CA2143143A1 - 3-phenylpyrrolidine derivatives - Google Patents
3-phenylpyrrolidine derivativesInfo
- Publication number
- CA2143143A1 CA2143143A1 CA002143143A CA2143143A CA2143143A1 CA 2143143 A1 CA2143143 A1 CA 2143143A1 CA 002143143 A CA002143143 A CA 002143143A CA 2143143 A CA2143143 A CA 2143143A CA 2143143 A1 CA2143143 A1 CA 2143143A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- matter
- oily
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
Abstract
3-phenylpyrrolidine derivatives of the present invention effectively inhibit phosphodiesterase (PDE) IV activities so that they can be used as medicaments for, such as, the asthma.
Description
-FIELD OF THE INVENTION
The present invention relates to new 3-phenylpyrrolidine derivatives, and more specifically, to 3-phenylpyrrolidine derivatives ensuring inhibition of phosphodiesterase (PDE) IV activities, their optical isomers, salts, N-oxide derivatives, hydrates or solvates.
BACKGROUND OF THE INVENTION
cAMP (cyclic adenosine 3', 5'-monophosphate) is an important second messenger which participates in relaxing bronchial smooth muscles and regulating functions of inflammatory cells. cAMP is decomposed into inactive 5'-AMP by phosphodiesterase (PDE). Accordingly, if the decompostion by PDE is suppressed to increase intracellular concentrations of cAMP, it is considered that bronchial dilatation and anti-inflammatory effects can be obtained so that concerns have been running high for PDE inhibitors (suppressing decomposition of cAMP) as antiasthmatics. Further, recently, five kinds of PDE isozymes (PDE I, II, III, IV, V) have been identified and their tissue distributions have been revealed(Adv. Second Messenger Phosphoprotein Res., 22, 1 (1988), Trends Pharm., Sci., 11, 150 (1990)).
Among the inhibitors against these isozymes, possibility has been pointed out that the specific inhibitors of PDE IV are effective in treating asthma (Thorax, 46, 512 (1991)). As a compound having the specific inhibition of PDE IV, for example, a compound (rolipram xxx) disclosed in Japanese First (unexamined) Patent Publication No. 50-157360 is known as represented by the following formula:
- 21431~3 o~
M e 0 (roliplam) ~ N H
Although various compounds are known other than the foregoing as disclosed in, such as, Japanese First (unexamined) Patent Publications No. 4-253945 and 5-117239, W09115451, W09207567, EP497564, W09219594 they have not applied clinically up to date so that development of further useful compounds has been demanded.
In J. Pharm. Sci., 73, 1585 (1984), a compound represented by the following formula and its dopaminergic activity are described:
0 M e M e 0 ~/`
N - P r n In Eur. J. Med., 27, 407 (1992), a compound represented by the following formula and its binding affinity at dopamine receptor are described:
O M e M e O
N ( C H2)4 M e In J. Org. Chem., 58, 36 (1993), a compound represented by the following formula is described, while no description about its physiological activity is provided:
Or~
H,~ ;~\ L
~N OB ut In Swiss Patent No. 526535, a compound represented by the following formula is described as a synthetic intermediate:
OM e M e O
``¢~"~
~ ~\N--C H 2 P h In Japanese Second (examined) Patent Publication No. 49-16871, a compound represented by the following formula is described as having antiulcer effect:
OM e Me O
N - ( C H 2 )3 NM e 2 In Japanese First (unexamined) Patent Publication No. 50-157360, a compound represented by the following general formula is described as a treating medicament for neuropsychosis:
-o R2 ~, R3 ~
X
wherein R' and R2 independently represent Cl - C5 alkyl; R3 represents hydrogen or methoxy; R4 represents hydrogen, alkyl, aryl or acyl; and X
represents oxygen or sulfur.
In Japanese Second (examined) Patent Publication No. 61-2660, a compound represented by the following general formula is described as~a treating medicament for neuropsychosis:
o R2 ~ O
~ \N - C - R 5 wherein R1 and R2 may be the same or different and independently represent Cl - C5 alkyl; and R5 represents C, - C8 0-aralkyl, 0-aryl, NH-aryl, NH-aralkyl, N-(alkyl)2, N-(aryl)2 or / aryl N
\ alkyl In Japanese First (unexamined) Patent Publication No. 2-121964, a compound represented by the following formula is described as having calcium antagonism:
21~3143 -O M e M e O
~"1-N - C H 2 C H 2 C H P h 2 In European Patent No. 344577, a compound represented by the following formula is described as a treating medicament for ischemia h rt d seas -ea l e.
O M e M e O
~ O
~ N - C H 2 C H 2 C H 2 - C - C H = C H
SUMMARY OF THE INVENTION
The present inventors have made researches for providing new compounds showing the inhibition of PDE IV and found out that specific 3-phenylpyrrolidine derivatives have excellent physiological activity, so as to reach completion of the present invention.
Specifically, the gist of the present invention resides in a 3-phenylpyrrolidine derivative of the following general formula (I):
o R2 ( I) ~ N - A - Y - R3 wherein R' represents Cl - C4 alkyl; R2 represents tetrahydrofuranyl, C, - C7 alkyl, Cl - C7 haloalkyl, C2 - C7 alkenyl, bicyclo [2,2,1] hept-2-yl or C3 - C8 cycloalkyl; A represents 21 l31~3 o S o o Il 11 11 1 - C -~ - C -~ - S - or - ~ -wherein R4 represents C1 - C4 alkyl; Y represents -O-, -S-, -O-N=CH-, -NR5- wherein R5 represents hydrogen, C, - C4 alkyl, C2 - C4 alkylcarbonyl or pyridylmethyl, or single bond; and R3 represents C1 -C7 alkyl which is unsubstituted or substituted by one or more substituents, or -(CH2)n-B wherein n is an integer of from O to 4, B
represents phenyl which is unsubstituted or substituted by one or more substituents, naphtyl which is unsubstituted or substituted by one or more substituents, or heterocyclic residue which is unsubstituted or substituted by one or more substituents; provided that when -A-Y-R3 is - C N H ~
R1 and R2 are not methyl at the same time.
The gist of the present invention further resides in optical isomers, salts, N-oxide derivatives, hydrates and solvates of the foregoing 3-phenylpyrrolidine derivative, and further resides in a pharmaceutical composition including such a compound as an effective component.
DETAILED DESCRIPTION OF THE INVENTION
Hereinbelow, the present invention will be described in detail.
In the following general formula (I):
21431~3 -o R 2 ( I) ~ N - A - Y - R3 R1 represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), preferably methyl or ethyl, and more preferably methyl.
R2 represents tetrahydrofuranyl, linear or branched C1 - C7 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-butyl, n-pentyl, l,2-dimethylpropyl, 1,1-dimethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methyl pentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2-trimethylpropyl, heptyl, 5-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl or the like) , C1 - C7 haloalkyl (chloromethyl, bromomethyl, dichloromethyl, 1-chloroethyl, 2-chloroethyl, 3-chloropropyl, 4-chlorobutyl, 5-chloropentyl, 6-chlorohexyl, difluoromethyl, trifluoromethyl or the like), C2 - C7 alkenyl (vinyl, allyl, 2-propenyl, isopropenyl, 3-butenyl, 4-pentenyl, 5-hexenyl or the like), bicyclo [2,2,1] hept-2-yl, or C3 - C8 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like), preferably tetrahydrofuranyl, C3 - C6 alkyl or C4 - C6 cycloalkyl, and more preferably cyclopentyl.
A represents o S o Il 11 11 - C -~ - C -~ - S 2 - or - p -o R 4 wherein R4 represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) , preferably O S O
Il 11 11 - C - or - C - , more preferably - C -Y represents -O-, -S-, -O-N=CH-, -NR5- where Rs represents hydrogen, linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) or pyridylmethyl, or single bond, preferably -O-, -S-, -NR5- (R5 is as defined above) or single bond, and more specifically -O- or -NR5- (R5 is as defined above).
R3 represents linear or branched Cl - C7 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) which is unsubstituted or substituted by one or more substituents selected from the ~roup consisting of halogen (fluorine, chlorine, bromine, iodine or the like), linear or branched C1 - C4 alkoxy (methoxy, isopropoxy, butoxy or the like), linear or branched C1 - C4 alkylthio (methylthio, isopropylthio, butylthio or the like), linear or branched C1 - C4 alkylsulfinyl (methylsulfinyl, isopropylsulfinyl, butylsulfinyl or the like), linear or branched C1 - C4 alkylsulfonyl (methylsulfonyl, isopropylsulfonyl, butylsulfonyl or the like), cyano, nitro, amino, hydroxy, carboxy, benzyloxy, C1 - C4 acyl (formyl, acetyl, propionyl or the like), C2 - C~ alkoxycarbonyl (methoxycarbonyl, ethoxycarbonyl or the like), linear or branched C1 - C4 alkylamino (methylamino, isopropylamino, butylamino or the like), linear or 21431~3 branched C2 - C6 dialkylamino (dimethylamino, diethylamino or the like), and O O
Il 11 - N R 6 - C - R 7 , - N R 6 - C - O R 7 , O O
Il 11 - N R 6 - C - N R 8 R 9 , - C - N R 8 R 9 and o wherein R6, R8 and R9 independently represent hydrogen or linear or branched Cl - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) and R7 represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), and preferably selected from the group consisting of halogen, C1 - C4 alkoxy, hydroxy, C1 - C4 alkylamino and C2 - C6 dialkylamino;
or -(CH2)n -B wherein n is an integer of from O to 4, preferably from O
to 2, and more preferably 1 or 2, and B represents phenyl, naphtyl or heterocyclic residue (thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl, pyrrolidinyl, piperidyl, piperidino, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, morpholinyl, morpholino, piperazinyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, 1,2,3,4-tetrahydroquinoline-2-yl, 5,6,7,8-tetrahydro-1,6-naphthyridine-6-yl, indolyl or the like, which includes 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen and 5 to 10 atoms in total for forming a ring, preferably thienyl, furyl, imidazolyl, pyrazolyl, pyridyl, pyrrolidinyl, piperidyl, piperidino, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, 1,2,3,4-tetrahydroquinoline-2-yl, 5,6,7,8-tetrahydro-1,6-naphthyridine-6-yl, indolyl, and more preferably pyridyl, piperidyl, piperidino, 214314~
-piperazinyl, pyridazinyl, pyrazinyl, pyrimidinyl or the like, which has a 6-membered ring and includes l or 2 nitrogen atoms as hetero atom), and wherein each of phenyl, naphtyl or heterocyclic residue referred to above is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen (fluorine, chlorine, bromine, iodine or the like), linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), linear or branched C1 - C4 alkoxy (methoxy, isopropoxy, butoxy or the like), linear or branched C1 - C4 alkylthio (methylthio, isopropylthio, butylthio or the like), linear or branched Cl - C4 alkylsulfinyl (methylsulfinyl, isopropylsulfinyl, butylsulfinyl or the like), linear or branched Cl - C4 alkylsulfonyl (methylsulfonyl, isopropylsulfonyl, butylsulfonyl or the like), cyano, nitro, amino, hydroxy, carboxy, C, - C4 acyl (formyl, acetyl, propionyl or the like), C2 - C4 alkoxycarbonyl (methoxycarbonyl, ethoxycarbonyl or the like), linear or branched C1 - C4 alkylamino (methylamino, isopropylamino, butylamino or the like), linear or branched C2 - C6 dialkylamino (dimethylamino, diethylamino or the like), O O
Il 11 - N R 6 - C - R 7 , - N R 6 - C - o R 7 O O
- N R ~ - C - N R 8 R 9 , -e - N R 8 R 9 wherein R6, R7, R8 and R9 are as defined above, 21~3143 -o R1o ~ O Rll wherein R' represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) and R" represents C3 - C8 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like) or linear or branched Cl - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), and pyridyl, and preferably selected from the group consisting of halogen, C1 - C4 alkyl, C, - C4 alkoxy, cyano, nitro, amino, hydroxy, ~
phenyl and pyridyl, and wherein B preferably represents heterocyclic residue which is unsubstituted or substituted by one or more substituents (as defined above), and more preferably heterocyclic residue which is unsubstitured.
In the general formula (I), when -A-Y-R3 is - C N H ~
R' and R2 are not methyl at the same time.
When R3 represents -(CH2)n-B (n is as defined above) and B is heterocyclic residue having one or more nitrogen atoms as hetero atom, it is possible that the compounds represented by the general formula (I) exist in the form of N-oxide derivatives. On the other hand, it is preferable that salts of the compounds represented by the general formula (I) are physiologically acceptable so that, for example, inorganic acid salts, such as, a hydrochloride, a hydrobromide, a hydroiodide, a sulfate, a phosphate, and organic acid salts, such as, -an oxalate, a maleate, a fumarate, a lactate, a malate, a citrate, a tartrate, a benzoate, a methanesulfonate, a p-toluenesulfonate can be enumerated. The compounds of the formula (I), their N-oxide derivatives and their salts can exist in the form of hydrates or solvates.
Accordingly, those hydrates and solvates are also included in the compounds of the present invention. As solvents of solvates, methanol, ethanol, isopropanol, acetone, ethyl acetate, methylene chloride and the like can be enumerated.
Further, the compounds of the general formula (I) include asymmetric carbon atoms so that isomers exist. These isomers are also included in the present invention.
The compound of the present invention can be prepared, for example, according to the following method:
Preparation Method 1 o R2 Rlo + R 3 - Y - A - X 1 N H
(II) ",/
o R2 base R 1 0 \r~
~ N - A - Y - R 3 wherein Rl, R2, R3, A and Y are as defined before, and X1 represents halogen.
The reaction is performed at a temperature range from 0 to 1500C
in the presence of organic base, such as, triethylamine, pyridine or N,N-diethylaniline or inorganic base, such as, sodium carbonate or sodium hydride, by use of no solvent or in a solvent, for example, .
21~3143 ketones, such as, acetone or ethyl methyl ketone, aromatic hydrocarbones, such as, benzene or toluene, ethers, such as, diethyl ether, tetrahydrofuran or dioxane, acetic esters, such as, ethyl acetate or isobutyl acetate, or in an aprotic polar solvent, such as, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidone.
A compound of the general formula (II) which is a starting material of the foregoing reaction can be prepared, for example, according to the following reaction formula from a compound of the following general formula (III) which are prepared according to the method described in Japanese First (unexamined) Patent Publication No.
50-157360 or the like.
o R 2 (III) ~
oR2 aluminum lithium hydride ~
(II) ~ N H
wherein pl and R2 are as defined before.
Preparation Method 2 When A is O S
Il 1~
- C - or - C -and Y represents -0-, -S-, -0-N=CH- or -NR5 - (R5 is as defined before), a compound of the following general formula (V) can also be prepared according to the following method:
o R 2 ~ x2 + R 3 - Y - H
/ \ 11 (IV) ~ N - C - C 1 o R 2 base ~ \ x2 r~ 11 ( V ) ~ N - C - Y - R 3 wherein Rl, R2, R3 and Y are as defined before, and x2 represents oxygen or sulfur.
The reaction is performed at a temperature range from 0 to 1500C
in the presence of organic base, such as, triethylamine, pyridine or N,N-diethylaniline or inorganic base, such as, sodium carbonate or sodium hydride, by use of no solvent or in a solvent, for example, ketones, such as, acetone or ethyl methyl ketone, aromatic hydrocarbones, such as, benzene or toluene, ethers, such as, diethyl ether, tetrahydrofuran or dioxane, acetic esters, such as, ethyl acetate or isobutyl acetate, or in an aprotic polar solvent, such as, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidone.
A compound of the foregoing general formula (IV) which is a starting material of the foregoing reaction can be prepared according to the following reaction formula from the starting material (II) in the preparation method 1.
21431~3 o R2 R 1 0 l x2 ~ C I - I - C 1 (II) ~ N H -o R 2 ~ x2 r~ 11 (IV) ~ N - C - C 1 wherein R', R2 and x2 are as defined before.
When the compound of the present invention is used as a treating medicament, the compound is dosed single or in combination with a pharmaceutically acceptable carrier. A composition of the carrier is determined based on solubility of the compound, chemical property of the compound, dosage route, dosage schedule and so on.
For example, the compound may be oral-dosed in the form of a granule medicine, a powder medicine, a tablet, a hard capsule medicine, a soft capsule medicine, a sirup medicine, an emulsion medicine, a suspended medicine or a liquid medicine, or may be intravenous-dosed, intramuscular-dosed or subcutaneous-dosed in the form of an injection medicine.
The compound may be powdered for injection and prepared to be used when necessary. The compound of the present invention may be used with pharmaceutical organic or inorganic and solid or liquid carrier or diluent which is suitable for oral, non-oral, throu~h-body or local dosing. As a forming agent to be used when producing the solid medicine, for example, lactose, sucrose, startch, talc, cellulose or dextrin may be used. The liquefied medicines for oral dosing, that is, the emulsion medicine, the sirup medicine, the suspended medicine, the -liquid medicine and the like, include the generally used inert diluent, such as, water or vegetable oil. These medicines can contain, other than the inert diluent, an auxiliary agent, such as, a wetting agent, a suspension assisting agent, a sweet agent, an aromatic, a coloring agent or a preserving agent. The liquefied medicine may be contained in a capsule made of a material, such as, gelatin which can be disintegrated in the body. As a solvent or a suspending agent to be used in the course of producing the medicine for non-oral dosing, such as, the medicine for injection, for example, water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate or lecithin can be enumerated. The known method can be used for making up the medicine.
When the compound of the present invention is used for oral dosing, a clinical dosing amount is, in general, O.Olmg to 1000mg per day, and preferably 0.01mg to 100mg, in case of an adult. It is naturally further preferable to properly increase or decrease a dosage amount depending on age, the condition of disease, the condition of patient, presence or absence of simultaneous dosing and so on. In case of the compound of the present invention, the foregoing dosing amount per day may be divided into two or three and dosed with proper intervals, or intermittent dosing may also be allowed.
On the other hand, when using the compound of the present invention as the injection medicine, it is preferable that a one-time dosage amount of 0.001mg to 100mg be continuously or intermittently dosed in case of an adult.
[Embodiment]
Hereinbelow, the present invention will be described in detail in terms of embodiments and test examples. The present invention is not limited to those embodiments and tests.
Embodiment 1 Preparation of 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethylaminocarbonyl) pyrrolidine (Compound No. 22 in Table 1):
216mg of 3-(aminomethyl) pyridine and 202mg of triethylamine were dissoved in 5ml of tetrahydrofuran. During agitation at a cold temperature, a solution obtained by dissolving 545mg of l-chloroformyl-3-(3-cyclopentyloxy-4-methoxyphenyl) pyrrolidine in 3ml of tetrahydrofuran was added in drops. After dropping, agitation was continued for 6 hours at a room temperature. Thereafter, the agitated solution was poured into ice water and then extracted with ethyl acetate. After organic layers were cleaned by water and dried over magnesium sulfate, it was concentrated under a reduced pressure. The residue was purified by means of the silica gel column chromatography to obtain 432mg of Compound No. 22 in Table 1.
Embodiment 2 Preparation of 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(ethoxycarbonyl) pyrrolidine (Compound No. 4 in Table 1):
460mg of 3-(3-cyclopentyloxy-4-methoxyphenyl) pyrrolidine and 214mg of triethylamine were dissoved in 15ml of dichloromethane and cooled in an ice bath. During agitation, 229mg of ethyl chloroformate was added in drops. After dropping, agitation was continued for 1 hour at a room temperature. Thereafter, the agitated solution was poured into ice water and then extracted with dichloromethane. After organic layers were cleaned by water and dried over magnesium sulfate, it was concentrated under a reduced pressure. The residue was purified by means of the silica gel column chromatography to obtain 92mg of Compound No. 4 in Table 1.
Embodiment 3 Compounds shown in Table 1 were synthesized according to the methods in Embodiments 1 and 2.
oR2 Table 1 compound R 1 R 2 - A - Y - R 3 physical No. properties O oily 1 M e ~ 11 matter - C - O B u t / O oily 2 M e ~ 11 matter - C - B u t O oily 3M e _~ 11 A matter \ J --C - O C H 2 ~
o oily 4M e ~ 11 matter \~ -C-OE t O oily M e ~ 11 matter \ ~ - C--C H 2 B u t O oily 6 M e / ¦ 11 matter \~ -C-OB un O oily 7 Me ~ -e~ matter O o oily 8 Me ~ I 11 matter \~ --C--O B u t 9 Me ~ 11 oily ~ - C ~ matter N
21~3143 Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physical No. properties Me ~ 11 oily - C - C H 2 ~ matter O m p 11 M e ~ ll H 125-126C
\~ --C--N--B u t O oily 12 M e ~ ll matter \ / - C - N M e 2 13 M e ~ 11 oi ly - C - O C H 2 ~ matter - C - O C H 2 ~ m p 14 M e ~ N 148-149C
M e ~ S O 3 H
M e _~ m p ~ - C - O C H 2 ~ H C l 108-114C
o 16 M e O - C - O C H 2 ~ 14P2-144C
o ~ ll A oily 17 M e ~ C O C H 2 ~ N~ matter - 21~3143 Table 1 (Continued) compound R I R 2 - A - Y - R 3 physical No. properties 18 M e ~ 11 A amorphous - C - O C H 2 N -~ O solid 19 M e ~ 11 A oi ly - C - O C H 2 ~ N matter Me ~ -S2 ~ matter 21 M e ~ 1l N oi 1Y
- C ~ ~ matter 22 Me O 11 m p- C - N H C H 2 ~ 129-130C
23 M e ~ 11 oily - C - O ~ matter 24 M e ~ 11 N oily - C - O C H 2 ~ matter o ~ ll A oily Me ~ -C-O~ ~ matter o ~o o ~ oi 1Y
26 M e ~ 11 N =,~ matter \ ~ --C--O C H
' 21431~3 Table 1 (Continued) compound R I R 2 - A - Y - R 3 physical No. properties 21 M e ~ N ~ M e oily ~ - C - O C H 2 ~ matter o 28 M e ~ 11 ~c==~ oily - C - O ~ N matter O oily 29 M e ~ 11 matter \ ~ - C - O C H 2 C H 2 N M e 2 oily M e ~ 11 matter '~,-' --C--O C H 2 C H 2 O H
~ oily 31 M e/ 1 11 matter - P (O E t) 2 O O M e oily O M e 33 M e ~ 11 1 A oily ~ - C - N - C H 2 ~ N~ matter 34 M e ~ O ~ N oily ll ~ matter - C - N ~
M eM e 11 A oily - C - O C H 2 ~ ~ matter 21~31~3 -Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physical No. properties 36 M e ~ 11 N oily ~ - C - O C H 2 C H 2 ~ matter o ~ 11 ~c==~ oily 37 M e ~ - C - O C H 2 ~ N matter O
38 M e ~ 11 A oily ~ - C - O C H 2 ~ ~-C 1 matter 39M e _ O 11 N oily - C - O - N = C H ~ matter M e O S oily - C - O C H 2 ~ matter 41 M e ~ N oily - C - O C H 2 ~ ~ matter N
42M e _ ~ 11 A oily - C - O C H 2~ matter N - N
43 M e ~ 11 N oily - C - O C H 2 ~ ~ matter Table 1 (Continued) compound Rl R2 - A - Y - R3 physical No. properties M e ~ oily 44M e ~ - C - O C H 2 ~ N ,N matter M e 45M e ~ oily - C - O C H2 ~ matter O ~ oily 46M e / ¦ ll N==~ matter \ / - C--O C H2 ~ N/~
Hereinbelow, NMR spectra are shown for the following compounds in the form of amorphous solid and oily matter, wherein the compounds are identified by Compound No. in Table 1.
-No.l 'HNMR(CDCl3)~ppm:1. 48(s,9H),1.53-1.
69 (m, 2H),1.73-2.00(m, 7H),2.14-2.28 (m lH),3.16-3.86 (m, 5H),3.83(s,3H),4.70 -4.81(m, lH),6.73-6.85(m,3H) No.2 'HNMR(CDCl3)~ppm:1. 28(s,9H),1.50-1.
68 (m, 2H),1.73-2.04(m,7H),2.13-2.33 (m lH),3.16-4.10(m, 5H),3.83(s,3H),4.71 -4.80(m, lH),6.71-6.85 (m, 3H) No.3 IHNMR(CDCl 3 ) ~ppm:l. 52-1.65(m,2H),l.
76-2.05 (m, 7H),2.18-2.36(m,lH),3.24-3 .92 (m, 5H),3.82(s,3H),4.72-4.79(m, 1 H) ,5.16(s,2H),6.74-6.83 (m, 3H),7.24-7.3 8(m,5H) No.4 'HNMR(CDCl 3 )~ppm:1.24-1.31(m, 3H),l.
54-1.70(m, 2H),1.74-2.04(m,7H),2.18-2 .32 (m, 1 H),3.22-3.90(m, 5H),3.83(s,3H) ,4.12-4.22 (m, 2H),4.77 (m, lH),6.74-6.8 4(m,3H) No.5 'HNMR(CDCl 3 ) ~ppm:1.08(brs,9H),1.54-2.38(m,1OH),2.21(brs,2H),3.22-4.06 (m ,5H),3.83(s,3H),4.70-4.80(m,lH),6.75 -6.81(m, 3H) No.6 'HNMR(CDCl3)~ppm:0.90-0.98(m,3H),l.
~1~3~
34-2.04(m,13H).2.18-2.32(m,1H).3.24-3.92(m,5H).3.82(s,3H),4.08-4.13(m,2H
).4.76(m,1H).6.74-6.83(s.3H) No.7 'HNMR(CDCI 3 ) ~ppm:1.56-1.70(m.2H).l.
76-2.42(m.8H).3.24-3.94(m.5H).3.83(b rs.3H).4.70-4.80(m.1H).6.71-6.82( m, 3 H).7.38-7.43(m,3H).7.54--7.56 (m, 2H) No.8 'HNMR(CDCI 3 ) ~ppm:1.48(s,9H),1.80-2.
28 (m, 4H),3.15-4.09(m, 9 H),3.84(s.3H), 4.89-5.00(m, 1 H).6.73(brs,1H),6.84(br s,2H) No.9 'HNMR(CDCl 3 ) ~ppm:l. 56-2.44 (m, 1 OH),3 .28-4.16 (m, 5H),3.82 and 3.84(a pair of s,3H),4.72-4.80(m, 1 H),6.70-6.83 (m ,3H),7.32-7.40(m,1H),7.86-7.92(m,1H) ,8.64-8.69(m, 1 H).8.81(m, 1 H) No.10 'HNMR(CDCI 3 ) ~ppm:1.56-2.42 (m, I OH),3 .26-4.08(m,5H).3.66(brs.2H),3.83(brs 3H),4.75 (m, I H),6.72-6.84(m,3H),7.24 -7.30(m,1H),7.68-7.74 (m, 1 H).8.50-8.5 2 (m, 2H) No.12 'HNMR(CDCI 3 ) ~ppm:l. 53-1.68(m,2H),I.
75-2.00(m,7H),2.15-2.28(m.lH).2.85(s .6H).3.18-3.31(m,1H).3.39(t.1H,J=9Hz 21431~3 ),3.46--3.61(m, 2H),3.70(d--d,lH,J=7 an d 9Hz),3.83(s,3H),4.71-4.80(m, lH),6.
74-6.84(m,3H) No.13 'HNMR(CDCI a ) ~p pm:l. 51-1.70(m,2H),l.
75-2.04(m,7H),2.18-2.34(m,1H),3.23-3 .53(m,3H),3.58-3.96 (m, 2H),3.83(s,3H) ,4.68-4.80(m, lH),5.18(s,2H),6.70-6.8 4 (m, 3H),7.26-7.35 (m, lH),7.73 (m, lH),8 .57 (m, lH),8.65 (m, lH) No.17 IHNMR(CDCl 3 ) ~ppm l. 51-1.70(m,2H),l.
75-2.09(m, 7H),2.20-2.35(m,1H),3.25-3 53 (m, 3H),3.63-3.75 (m, lH),3.80-3.93( m,lH),3.83(s,3H),4.71-4.81(m, lH),5.1 3(brs,2H),6.70-6.86(m,3H),7.27 (m, 2H) ,8.16 (m, lH),8.28 (m, lH) No.18 ~HNMR(CDCl 3 ) ~ippm:l. 54-2.08 (m, 9H),2.
22-2.36 (m, lH),3.28-3.92(m,5H),3.83(s ,3H),4.76 (m, lH),5.12(brs,2H),6.75-6.
84 (m, 3H),7.27-7.32 (m, 2H),8.17-8.21(m ,2H) No.l9 'HNMR(CDCl 3 ) ~ppm:1.56-2.12(m,9H),2.
24-2.36 (m, lH),3.30-3.90(m,5H),3.83(s ,3H),4.77 (m, lH),5.19(brs,2H),6.76-6.
86 (m, 3H),7.26-7.30(m, 2H),8.57-8.61(m ,2H) No.20 'HNMR(CDCl 3 ) ~ppm:1.56-2.06 (m, 9H),2.
14-2.28 (m, lH),3.16-3.90(m, 5H),3.81(s 3H),4.68-4.76 (m, lH),6.61-6.78 (m, 3H) ,7.48-7.56 (m, lH),8.13-8.16 (m, lH),8.9 4(brs,1H),9.10(brs,lH) No.21 'HNMR(CDCI 3 ) ~ppm:l. 56-2.16 (m, 9 H),2.
30-2.40(m,lH),3.30-3.48 (m, lH),3.64-4 .26 (m, 4H),3.83(brs,3H),4.74-4.80(m,1 H),6.77-6.83(m,3H)-,8.52-8.56(m,lH),8 .62-8.66(m,1H),9.17(s,1H) No.23 IHNMR(CDCl 3 ) ~ppm:1.56-2.18(m,9H),2.
26-2.42(m,lH),3.34-4.16(m,5H),3.83(s ,3H),4.72-4.80(m,1H),6.78-6.88(m,3H) ,7.32(m,1H),7.55-7.60(m,1H),8.47(m,2 H) No.24 'HNMR(CDCl 3 ) ~ppm:l. 50-1.70(m, 2H),l.
73-2.04 (m, 7H),2.20-2.35(m,1H),3.25-3 .59(m,3H),3.66-3.78 (m, lH),3.83(s,3H) ,3.86-3.96(m,1H),4.70-4.79(m, lH),5.2 8(brs,2H),6.71-6.84 (m, 3H),7.16-7.26( m, lH),7.39(t,1H,J=7Hz),7.65-7.74 (m, 1 H),8.58 (m, lH),8.65 (m, lH) No.25 'HNMR(CDCl 3 ) ~ppm:1.56-2.16(m,9H),2.
28-2.44 (m, lH),3.34-4.06 (m, 5H),3.84(s 21931~3 ,3H),4.74-4.80(m,1H),6.77-6.83(m,3H) ,7.23-7.27 (m, 2H),8.06-8.09(m,1H),8.1 9(s,lH) No.26 IHNMR(CDCI 3 ) ~ppm:1.50-1.70(m,2H)1.7 5-2.10(m,7H),2.22-2.40(m,1H),3.30-3.
62 (m, 3H),3.68-3.83 (m, lH),3.84(s,3H), 3.89-4.00(m, lH),4.70-4.81(m, lH),5.44 (brs,2H),6.74-6.86 (m, 3H),7.20-7.35(m 2H~,7.36-7.45 (m, 1 H),8.25 (m, 1 H) No.27(diastereo mix ture) IHNMR(CDCl 3 ) ~ ppm:l. 52-2.40(m, 1 7H),2 .27 and 2.29(a pair of s,3H),2.78-2.
94(m,2H),3.24-4.08 (m, 7H),3.83(s,3H), 4.72-4.80(m,1H),6.75-6.86 (m, 3H) No.28 IHNMR(CDCI 3 ) ~ppm:l. 56-1.72(m,2H),l.
76-1.94 (m, 6H),2.04-2.16 (m, 1 H),2.33-2 .42(m,1H),3.34-3.93 (m, 5H),3.83(s,3H) ,4.73-4.80(m,1H),6.32-6.38(m,2H),6.7 5-6.86 (m, 3H),7.72-7.77(m,2H) No.29 IHNMR(CDCl 3 ) ~ppm:1.51-1.69(m,2H),l.
74-2.01(m,7H),2.15-2.30(m,1H),2.29(s ,3H),2.31(s,3H),2.60(m, 2H),3.22-3.50 (m,3H),3.57-3.72(m,1H),3.75-3.91(m,1 H),3.82(s,3H),4.22(t,2H,J=5Hz),4.70-4.80(m,1H),6.71-6.84(m,3H) No.30 21431~3 IHNMR(CDCl 3 ) ~ippm:l. 51-1. 69 (m, 2H).l.
74-2.0 5 (m, 7H).2.19-2.34 (m, lH).2.80(b rs.lH).3.23-3.74 (m, 7H),3.83(s,3H),4.
23--4.31(m.2H).4.70--4. 81 (m, lH). 6. 72--6 85 (m, 3H) No.31 - IHNMR(CDCl 3 ) ~ppm:l. 30-1.37 (m, 6H).l.
5 4-1. 6 8 (m, 2H).1.78-2.04 (m, 7H).2.20-2 .32 (m, lH).3.10-3.1 8 (m, lH).3.24-3. 50 ( m, 3H).3. 6 0-3. 68 (m, lH),3. 8 3(s.3H).4.0 0-4.1 6 (m, 4H).4.72-4.80(m, lH).6.7 5-6 83 (m, 3H) No.32 IHNMR(CDCI 3 ) ~ppm:l. 56-2.06 (m, 9H).2.
18-2.30(m, lH).2.72-2.9 6 (m, 2H).3.24-3 .92 (m, 7H).3. 8 3(s.3H).3. 8 5(s.3H).3. 8 6 (s.3H).4.40(s.2H).4.72-4. 80 (m, lH),6.
59(s.1H).6.62(s.1H).6.77-6. 86 (s, 3H) No.33 IHNMR(CDCl 3 ) (~ppm:l. 56-2.06 (m, 9H),2.
16-2.32 (m, lH).2. 81 (s, 3H).3.22-3.36 (m .lH).3.43(t.lH.J=9Hz).3.54-3.60(m, 2H
).3.72-3. 81 (m, lH).3.83(s.3H).4.43(d.
lH,J=12Hz).4. 5 O(d.lH.J=12Hz),4.72--4.
80(m, lH).6.7 5--6. 84 (m, 3H),7.2 5--7.30(m lH).7. 6 8-7.71(m, lH).8.52-8.5 6 (m, 2H) No.34(diastereo m ixture) 'HNMR(CDCl 3 ) ~p pm:l. 5 6- 2.08 (m, lOH).2 .18-2.36 (m, 2H).3.20-3.94(m.1OH).3.83 (s,3H),4.72-4.80(m,1H),6.76-6.84(m,3 H),7.16-7.19(m, 2H),8.53-8.55 (m, 2H) No.35 IHNMR(CDCl3)~ppm:1. 90- 2.10(m, 1 H),2.
19-2.33 (m, 1 H),3.24-3.51(m, 3H),3.60-3 . 9S (m, 2H),3.87(s,6H),5.18(brs.2H),6.
70-6.86 (m,- 3H),7.27-7.34 (m, 1 H),7.68-7 .76 (m, 1 H),8.57 (m, 1 H),8.65(m,1H) No.36 'HNMR(CDCl3)~ppm:1. 56-2.06 (m, 9H),2.
16-2.28 (m, lH),3.12-3.88(m,7H),3.83(s 3H),4.48(t,2H,J=7Hz),4.75 (m, 1 Hj,6.7 2-6.83 (m, 3H),7.10-7.24 (m, 2H),7.54-7.
64 (m, 1 H),8.54(m,1H) No.37 'HNMR(CDCl3) ôppm:l. 56-2.12 (m, 9H),2.
22-2.38 (m, 1 H),3.50-3.58 (m, 3H),3.68-3 94 (m, 2H),3.83(s,3H),4.77 (m, 1 H),5.16 (brs,2H),6.76-6.85(m,3H),7.12-7.21(m lH),7.31-7.33 (m, 1 H),8.34-8.38 (m, 1 H) No.38 IHNMR(CDCl3)~ppm:1. 51-1. 68 (m, 2H),l.
73-2.04 (m, 7H),2.19-2.33 (m, 1 H),3.23-3 52(m,3H),3.57-3.92 (m, 2H),3.83(s,3H) 4.70-4.80(m, lH), 5.15(brs,2H),6.70-6 .84(m,3H),7.29-7.36( m, 1 H),7.67-7.74( m, 1 H),8.42 (m, lH) No.39 HNMR(CDCl3)~ppm:1.50-1.71(m,2H),l.
21431~3 74-2.11(m,7H),2.23-2.40(m, lH),3.30-3 .64 (m, 3H),3.70-3.85 (m, lH),3.84(s,3H) ,3.90-4.05(m,1H),4.71-4.83 (m, lH),6.7 3-6.85 (m, 3H),7.33(t,lH,J=9Hz),7.76(t ,lH,J=9Hz),8.14(d,lH,J=9Hz),8.43(d,1 H,J=9Hz),8.64(brs,lH) No.40 IHNMR(CDCl3)~ ppm:l. 56-2.16 (m, 9H),2.
28-2.42 (m, lH),3.32-4.28 (m, 5H),3.83(b rs,3H),4.72-4.78 (m, lH),5.56 and 5.57 (a pair of s,2H),6.71-6.84 (m, 3H),7.2 6-7.34 (m, lH),7.72-7.76 (m, lH),8.54-8.
62 (m, lH),8.65-8.69(m,1H) No.41 IHNMR(CDCl3) ôppm:l. 56-2.18 (m, 9H),2.
32-2.42(m,1H),3.32-3.46 (m, lH),3.54-3 .66 (m, lH),3.72-3.90(m,2H),3.83(s,3H) 3.94-4.06 (m, lH),4.48(brs,1H),4.60(s 2H),4.72-4.80(m, lH)6.75-6.85 (m, 3H), 7.28-7.30(m,lH),8.02(s,lH) No.42 IHNMR(CDCl3)0ppm:1.56-2.08 (m, 9H),2.
22-2.36(m,lH),3.26-3.56 (m, 3H),3.66-3 .96 (m, 2H),3.83(s,3H),4.72-4.80(m, lH) ,5.50 and 5.51(a pair of s,2H),6.75-6.84 (m, 3H),7.46--7.53(m,1H),7.58-7.66 (m,lH),9.14-9.16(m,1H) No.43 'HNMR(cDcl3)~ppm:l. 56-2.10(m, 9H),2.
-20-2.36 (m, lH),3.28-3.56 (m,3H),3.70-3 .96 (m,2H),3.83 (s,3H),4.77 (m, lH),5.32 and 5.33 (a pair of s,2H),6.75-6.84 ( m,3H),8.53-8.56 (m,2H),8.70-8.71 (m, lH
) No.44 'HNMR (CDCl 3 ) ~p pm:l.50-1.70 (m,2H),1.
74-2.04 (m,7H),2.18-2.40 (m, lH),2.24 (b rs,3H),3.22-3.92 (m,5H),3.82 (brs,6H), 4.70-4.80 (m, lH),5.10 (brs,2H),6.08 (br s, lH),6.69-6.84 (m,3H) No.45 'HNMR (CDCI 3 ) ~ppm:1.50-1.69 (m,2H),1.
75-2.03 (m,7H),2.18-2.30 (m, lH),3.23-3 .93 (m,5H),3.82 (s,3H),4.70-4.80 (m, lH) ,5.02 (brs,2H),6.46 (m, lH),6.70-6.84 (m ,3H),7.39 (m, lH),7.48 (m, lH) No.46 'HNMR (CDCI 3 ) ~ppm:1.56-2.12 (m,9H),2.
22-2.38 (m, lH),3.30-3.58 (m,3H),3.68-3 .96 (m,2H),3.84 (s,3H),4.74-4.80 (m, lH) ,5.27 (brs,2H),6.76-6.85 (m,3H),8.02 (m , lH),8.17-8.19 (m, lH),8.41-8.43 (m, lH) 21~31~3 -Embodiment 4 Preparation of (+)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine and (-)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine:
145mg of (+ )-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine (Compound No. 13 in Table 1) was separated with HPLC (eluent: ethanol/hexane = 10/90) using the optical isomer separation column CHIRALPAKAS (Daicel xxx) to obtain (+)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolldine (Compound No. 47) 64mg [ a ]D25 = +22.3 (cO.91, methanol), and (-)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyrid ylmethoxycarbonyl) pyrrolidine (Compound No. 48) 61mg [ a ]D25 = -23.7 (c1.02, methanol).
Embodiment 5 Compounds shown in Table 1 (shown hereinbelow) were synthesized according to the methods in Embodiments 1 and 2.
- 21~314~
Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physical No. properties o 49M e _ ~ ll / /7- N \ oily ~ ~ 2 ~ )2 matter o 50 M e ~ - C - N ~ matter 51M e _ ~ ll /7-~ oily ~ - C S C H 2 ~ matter o 52 M e ~ ll /r ~ oily \- C C H 2 C H 2 ~ matter 53 M e ~ 11 /r ~\ oily - C N H C H 2 ~ \~- B u n matter O oily 54 M e ~ 11 matter \~-' - C O C H 2 C H 2 S 2 M e o ~ 0 11 M e _/ 11 C C H 3 oily - C N / ~ matter N
o 56 M e ~ 11 N -~ oily ~- C N H C H 2 ~ matter o 57 M e ~ ll ~7-~ oily - C N H C H 2 C H 2 ~ N ~ matter Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physica1 No. properties 58 M e ~ - C N O M e 12P0-123C
o 59 M e ~ ll /r ~ oily ~ - C N H ~ ~ matter M e ~ - C N H C H 2 C H 2 ~ ~ matYter 61M e ~ 11 ~ m p 62M e ~ 2 2~ matter M e 63M e _ ~ 11 ~ amorphous - ~ - C N H C H 2 ~ S~ solid Il ~ amorphous 64M e ~ - C N H ~ N solid In Table 1, Me represents methyl, Et ethyl, Bun n-butyl and But tert-butyl.
- 21~314~
-No.49 'HNMR(CDCl 3 ) ~ppm:l. 50-2.10(m, 9H).2.
20-2.38 (m, 1 H),3.2-3.7 (m, 4H),3.8(m,1H
),3.82(s,3H),4.23-4.57 (m, 4H),4.60-4.
83(m,1H),6.63-6.93 (m, 3H),7.20-7.40(m 2H),7.57-7.76 (m, 2H),8.40-8.68 (m, 4H) No.50 IHNMR(CDCl 3 ) l~p pm:l. 49-2.10 (m, 9H),2.
20-2.36 (m, lH),2.9-3.8 (m, 9H),3.83(s,3 H),4.73(s,2H),4.70-4.80(m, 1 H),6.70-6 85 (m, 3H),6.80(dd,1H),7.41(d,1H),8.4 3(d,1H) No.51 IHNMR(CDCl 3 ) ~ppm:l. 49-1.71(m, 2H),l.
74-2.09(m, 7H),2.20-2.36 (m, 1 H),3.2-4.
1 (m, 5H),3.82(s,3H),4.20(s,2H),4.69-4 79(m,1H),6.69-6.84 (m, 3H),7.19-7.41( m,5H) No.52 IHNMR(CDCl 3 ) ~ppm:1.53-1.70(m,2H),l.
75-2.08 (m, 7H).2.20-2.38 (m, lH).3.2-4.
1 (m, 5H),3.82(s,3H),4.13 (m, 2H),4.65 (m ,2H),4.70-4.80(m, 1 H),6.70-6.85 (m, 3H) ,7.25-7.43(m,5H) No.53 IHNMR(CDCl 3 ) ~ppm:O. 9 4(t,3H),1.39(m, 2H),1.51-2.09(m,1lH),2.23-2.35(m,lH) ,2.77(t,2H),3.25-3.48(m,3H),3.55-3.6 6 (m, 1 H),3.8(m,1H),3.83(s,3H),4.44(d, -2H). 4. 53(t,lH), 4. 6 9 - 4. 79(m, lH), 6. 73-6. 8 5 (m, 3H),7.11(d,1H),7. 6 O(dd,lH), 8.
4 4 (d,lH) No.5 4 'HNMR(CDC1 3 ) ~p p m : 1. 53-1.70(m, 2H),1.
75-2.0 8 (m, 7H),2.19-2.35 (m, lH),3.00(m ,3H),3.20-3.51(m,5H),3.55-3.90(m, 2H) 3. 8 3(s,3H), 4. 57(m,2H), 4. 70--4. 81 (m,l H). 6. 70- 6. 8 5(m,3H) No.55 'HNMR(CDCl 3 ) ~ippm:1.52-1. 74 (m,2H),l.
75-2.07(m,7H),2.17(s, 3 H),2.20-2. 3 8 (m lH), 3. 1 - 3. 9 (m,5H), 3. 8 3 (s, 3 H), 4. 6 3 - 4 9 3 (m, 3 H), 6. 5 4 - 6. 84(m,3H),7.27 (m, lH) 7.75 (m, lH),8. 4 7-8. 6 3 (m, 2H) No.5 6 IHNMR(CDC1 3 ) ~p p m : 1. 4 7-1.7 4 (m, 2H),1.
7 4 - 2.10(m, 7H),2.18-2.37 (m, lH),3.1 8 - 3 .53 (m, 3H),3.58-3.94 (m, 2H),3.80(s,3H) , 4. 5 4 (d,2H), 4. 7 0 - 4. 80(m, lH),5.8 4 (t,l H), 6. 73-6.83 (m, 3 H),7.15 (m, lH),7. 3 O(m ,lH),7.62(m,1H),8.49(m,1H) No.57 'HNMR(CDCl 3 ) ~p pm:l.50-1.70(m,2H),l.
72-2.04(m,7H),2.18-2. 3 4 (m, lH), 3. Ol(t 2H), 3. 22- 3. 85 (m, 7H), 3. 8 3 (s, 3 H),4.68 -4.79(m, lH),5. 34 ( t,lH), 6. 73--6. 83(m, 3 H), 7. 08-7.20(m, 2H),7.57-7.6 4 (m, lH),8 . 5 0 (m, lH) No.59 IHNMR(CDCl 3 ) ~ppm:l. 47--2.15 (m, 9H),2.
22-2.42 (m, lH),3.28-4.03 (m, 5H),3.83(s 3H),4.70--4.80(m, 1 H),6.61(bs,1H),6.7 5--6.85 (m, 3H),7.22 (m, 1 H),8.09(m,1H),8 .24(m,1H),8.48(m,1H) No.60 'HNMR(CDCl 3 ) ~ppm:l. 48-1.70(m, 2H),l.
70-2.05 (m, 7H),2.16-2.33 (m, lH),2.98(t 2H),3.16-3.33 (m, 3H),3.45-3.75 (m, 4H) 3.81(s,3H),4.37(t,1H),4.70-4.80(m, H),6.65-6.95 (m, 3H),7.00(m, 1 H),7.06-7 23 (m, 2H),7.35 (m, 1 H),7.62 (m, 1 H),8.67 (bs,lH) No.62 IHNMR(CDCl 3 ) ôppm:l. 50-1.70 (m, 2H),1.
75-2.05 (m, 7H),2.18-2.35 (m, lH),2.81(t 2H),3.23-3.55 (m, 6H),3.59(s,3H),3.70 -3.87 (m, 1 H),3.83(s,3H),4.45(t,1H),4.
70-4.80(m, 1 H),5.92 (m, 1 H),6.05 (m, 1 H), 6.57(m,1H),6.73-6.83(m,3H) No.63 IHNMR(CDCI 3 ) ôppm:l. 52-1.70 (m, 2H),l.
74--2.07(m,7H),2.18-2.39(m, 1 H),3.3-3.
The present invention relates to new 3-phenylpyrrolidine derivatives, and more specifically, to 3-phenylpyrrolidine derivatives ensuring inhibition of phosphodiesterase (PDE) IV activities, their optical isomers, salts, N-oxide derivatives, hydrates or solvates.
BACKGROUND OF THE INVENTION
cAMP (cyclic adenosine 3', 5'-monophosphate) is an important second messenger which participates in relaxing bronchial smooth muscles and regulating functions of inflammatory cells. cAMP is decomposed into inactive 5'-AMP by phosphodiesterase (PDE). Accordingly, if the decompostion by PDE is suppressed to increase intracellular concentrations of cAMP, it is considered that bronchial dilatation and anti-inflammatory effects can be obtained so that concerns have been running high for PDE inhibitors (suppressing decomposition of cAMP) as antiasthmatics. Further, recently, five kinds of PDE isozymes (PDE I, II, III, IV, V) have been identified and their tissue distributions have been revealed(Adv. Second Messenger Phosphoprotein Res., 22, 1 (1988), Trends Pharm., Sci., 11, 150 (1990)).
Among the inhibitors against these isozymes, possibility has been pointed out that the specific inhibitors of PDE IV are effective in treating asthma (Thorax, 46, 512 (1991)). As a compound having the specific inhibition of PDE IV, for example, a compound (rolipram xxx) disclosed in Japanese First (unexamined) Patent Publication No. 50-157360 is known as represented by the following formula:
- 21431~3 o~
M e 0 (roliplam) ~ N H
Although various compounds are known other than the foregoing as disclosed in, such as, Japanese First (unexamined) Patent Publications No. 4-253945 and 5-117239, W09115451, W09207567, EP497564, W09219594 they have not applied clinically up to date so that development of further useful compounds has been demanded.
In J. Pharm. Sci., 73, 1585 (1984), a compound represented by the following formula and its dopaminergic activity are described:
0 M e M e 0 ~/`
N - P r n In Eur. J. Med., 27, 407 (1992), a compound represented by the following formula and its binding affinity at dopamine receptor are described:
O M e M e O
N ( C H2)4 M e In J. Org. Chem., 58, 36 (1993), a compound represented by the following formula is described, while no description about its physiological activity is provided:
Or~
H,~ ;~\ L
~N OB ut In Swiss Patent No. 526535, a compound represented by the following formula is described as a synthetic intermediate:
OM e M e O
``¢~"~
~ ~\N--C H 2 P h In Japanese Second (examined) Patent Publication No. 49-16871, a compound represented by the following formula is described as having antiulcer effect:
OM e Me O
N - ( C H 2 )3 NM e 2 In Japanese First (unexamined) Patent Publication No. 50-157360, a compound represented by the following general formula is described as a treating medicament for neuropsychosis:
-o R2 ~, R3 ~
X
wherein R' and R2 independently represent Cl - C5 alkyl; R3 represents hydrogen or methoxy; R4 represents hydrogen, alkyl, aryl or acyl; and X
represents oxygen or sulfur.
In Japanese Second (examined) Patent Publication No. 61-2660, a compound represented by the following general formula is described as~a treating medicament for neuropsychosis:
o R2 ~ O
~ \N - C - R 5 wherein R1 and R2 may be the same or different and independently represent Cl - C5 alkyl; and R5 represents C, - C8 0-aralkyl, 0-aryl, NH-aryl, NH-aralkyl, N-(alkyl)2, N-(aryl)2 or / aryl N
\ alkyl In Japanese First (unexamined) Patent Publication No. 2-121964, a compound represented by the following formula is described as having calcium antagonism:
21~3143 -O M e M e O
~"1-N - C H 2 C H 2 C H P h 2 In European Patent No. 344577, a compound represented by the following formula is described as a treating medicament for ischemia h rt d seas -ea l e.
O M e M e O
~ O
~ N - C H 2 C H 2 C H 2 - C - C H = C H
SUMMARY OF THE INVENTION
The present inventors have made researches for providing new compounds showing the inhibition of PDE IV and found out that specific 3-phenylpyrrolidine derivatives have excellent physiological activity, so as to reach completion of the present invention.
Specifically, the gist of the present invention resides in a 3-phenylpyrrolidine derivative of the following general formula (I):
o R2 ( I) ~ N - A - Y - R3 wherein R' represents Cl - C4 alkyl; R2 represents tetrahydrofuranyl, C, - C7 alkyl, Cl - C7 haloalkyl, C2 - C7 alkenyl, bicyclo [2,2,1] hept-2-yl or C3 - C8 cycloalkyl; A represents 21 l31~3 o S o o Il 11 11 1 - C -~ - C -~ - S - or - ~ -wherein R4 represents C1 - C4 alkyl; Y represents -O-, -S-, -O-N=CH-, -NR5- wherein R5 represents hydrogen, C, - C4 alkyl, C2 - C4 alkylcarbonyl or pyridylmethyl, or single bond; and R3 represents C1 -C7 alkyl which is unsubstituted or substituted by one or more substituents, or -(CH2)n-B wherein n is an integer of from O to 4, B
represents phenyl which is unsubstituted or substituted by one or more substituents, naphtyl which is unsubstituted or substituted by one or more substituents, or heterocyclic residue which is unsubstituted or substituted by one or more substituents; provided that when -A-Y-R3 is - C N H ~
R1 and R2 are not methyl at the same time.
The gist of the present invention further resides in optical isomers, salts, N-oxide derivatives, hydrates and solvates of the foregoing 3-phenylpyrrolidine derivative, and further resides in a pharmaceutical composition including such a compound as an effective component.
DETAILED DESCRIPTION OF THE INVENTION
Hereinbelow, the present invention will be described in detail.
In the following general formula (I):
21431~3 -o R 2 ( I) ~ N - A - Y - R3 R1 represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), preferably methyl or ethyl, and more preferably methyl.
R2 represents tetrahydrofuranyl, linear or branched C1 - C7 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-butyl, n-pentyl, l,2-dimethylpropyl, 1,1-dimethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methyl pentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2-trimethylpropyl, heptyl, 5-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl or the like) , C1 - C7 haloalkyl (chloromethyl, bromomethyl, dichloromethyl, 1-chloroethyl, 2-chloroethyl, 3-chloropropyl, 4-chlorobutyl, 5-chloropentyl, 6-chlorohexyl, difluoromethyl, trifluoromethyl or the like), C2 - C7 alkenyl (vinyl, allyl, 2-propenyl, isopropenyl, 3-butenyl, 4-pentenyl, 5-hexenyl or the like), bicyclo [2,2,1] hept-2-yl, or C3 - C8 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like), preferably tetrahydrofuranyl, C3 - C6 alkyl or C4 - C6 cycloalkyl, and more preferably cyclopentyl.
A represents o S o Il 11 11 - C -~ - C -~ - S 2 - or - p -o R 4 wherein R4 represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) , preferably O S O
Il 11 11 - C - or - C - , more preferably - C -Y represents -O-, -S-, -O-N=CH-, -NR5- where Rs represents hydrogen, linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) or pyridylmethyl, or single bond, preferably -O-, -S-, -NR5- (R5 is as defined above) or single bond, and more specifically -O- or -NR5- (R5 is as defined above).
R3 represents linear or branched Cl - C7 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) which is unsubstituted or substituted by one or more substituents selected from the ~roup consisting of halogen (fluorine, chlorine, bromine, iodine or the like), linear or branched C1 - C4 alkoxy (methoxy, isopropoxy, butoxy or the like), linear or branched C1 - C4 alkylthio (methylthio, isopropylthio, butylthio or the like), linear or branched C1 - C4 alkylsulfinyl (methylsulfinyl, isopropylsulfinyl, butylsulfinyl or the like), linear or branched C1 - C4 alkylsulfonyl (methylsulfonyl, isopropylsulfonyl, butylsulfonyl or the like), cyano, nitro, amino, hydroxy, carboxy, benzyloxy, C1 - C4 acyl (formyl, acetyl, propionyl or the like), C2 - C~ alkoxycarbonyl (methoxycarbonyl, ethoxycarbonyl or the like), linear or branched C1 - C4 alkylamino (methylamino, isopropylamino, butylamino or the like), linear or 21431~3 branched C2 - C6 dialkylamino (dimethylamino, diethylamino or the like), and O O
Il 11 - N R 6 - C - R 7 , - N R 6 - C - O R 7 , O O
Il 11 - N R 6 - C - N R 8 R 9 , - C - N R 8 R 9 and o wherein R6, R8 and R9 independently represent hydrogen or linear or branched Cl - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) and R7 represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), and preferably selected from the group consisting of halogen, C1 - C4 alkoxy, hydroxy, C1 - C4 alkylamino and C2 - C6 dialkylamino;
or -(CH2)n -B wherein n is an integer of from O to 4, preferably from O
to 2, and more preferably 1 or 2, and B represents phenyl, naphtyl or heterocyclic residue (thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl, pyrrolidinyl, piperidyl, piperidino, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, morpholinyl, morpholino, piperazinyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, 1,2,3,4-tetrahydroquinoline-2-yl, 5,6,7,8-tetrahydro-1,6-naphthyridine-6-yl, indolyl or the like, which includes 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen and 5 to 10 atoms in total for forming a ring, preferably thienyl, furyl, imidazolyl, pyrazolyl, pyridyl, pyrrolidinyl, piperidyl, piperidino, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, 1,2,3,4-tetrahydroquinoline-2-yl, 5,6,7,8-tetrahydro-1,6-naphthyridine-6-yl, indolyl, and more preferably pyridyl, piperidyl, piperidino, 214314~
-piperazinyl, pyridazinyl, pyrazinyl, pyrimidinyl or the like, which has a 6-membered ring and includes l or 2 nitrogen atoms as hetero atom), and wherein each of phenyl, naphtyl or heterocyclic residue referred to above is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen (fluorine, chlorine, bromine, iodine or the like), linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), linear or branched C1 - C4 alkoxy (methoxy, isopropoxy, butoxy or the like), linear or branched C1 - C4 alkylthio (methylthio, isopropylthio, butylthio or the like), linear or branched Cl - C4 alkylsulfinyl (methylsulfinyl, isopropylsulfinyl, butylsulfinyl or the like), linear or branched Cl - C4 alkylsulfonyl (methylsulfonyl, isopropylsulfonyl, butylsulfonyl or the like), cyano, nitro, amino, hydroxy, carboxy, C, - C4 acyl (formyl, acetyl, propionyl or the like), C2 - C4 alkoxycarbonyl (methoxycarbonyl, ethoxycarbonyl or the like), linear or branched C1 - C4 alkylamino (methylamino, isopropylamino, butylamino or the like), linear or branched C2 - C6 dialkylamino (dimethylamino, diethylamino or the like), O O
Il 11 - N R 6 - C - R 7 , - N R 6 - C - o R 7 O O
- N R ~ - C - N R 8 R 9 , -e - N R 8 R 9 wherein R6, R7, R8 and R9 are as defined above, 21~3143 -o R1o ~ O Rll wherein R' represents linear or branched C1 - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like) and R" represents C3 - C8 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like) or linear or branched Cl - C4 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl or the like), and pyridyl, and preferably selected from the group consisting of halogen, C1 - C4 alkyl, C, - C4 alkoxy, cyano, nitro, amino, hydroxy, ~
phenyl and pyridyl, and wherein B preferably represents heterocyclic residue which is unsubstituted or substituted by one or more substituents (as defined above), and more preferably heterocyclic residue which is unsubstitured.
In the general formula (I), when -A-Y-R3 is - C N H ~
R' and R2 are not methyl at the same time.
When R3 represents -(CH2)n-B (n is as defined above) and B is heterocyclic residue having one or more nitrogen atoms as hetero atom, it is possible that the compounds represented by the general formula (I) exist in the form of N-oxide derivatives. On the other hand, it is preferable that salts of the compounds represented by the general formula (I) are physiologically acceptable so that, for example, inorganic acid salts, such as, a hydrochloride, a hydrobromide, a hydroiodide, a sulfate, a phosphate, and organic acid salts, such as, -an oxalate, a maleate, a fumarate, a lactate, a malate, a citrate, a tartrate, a benzoate, a methanesulfonate, a p-toluenesulfonate can be enumerated. The compounds of the formula (I), their N-oxide derivatives and their salts can exist in the form of hydrates or solvates.
Accordingly, those hydrates and solvates are also included in the compounds of the present invention. As solvents of solvates, methanol, ethanol, isopropanol, acetone, ethyl acetate, methylene chloride and the like can be enumerated.
Further, the compounds of the general formula (I) include asymmetric carbon atoms so that isomers exist. These isomers are also included in the present invention.
The compound of the present invention can be prepared, for example, according to the following method:
Preparation Method 1 o R2 Rlo + R 3 - Y - A - X 1 N H
(II) ",/
o R2 base R 1 0 \r~
~ N - A - Y - R 3 wherein Rl, R2, R3, A and Y are as defined before, and X1 represents halogen.
The reaction is performed at a temperature range from 0 to 1500C
in the presence of organic base, such as, triethylamine, pyridine or N,N-diethylaniline or inorganic base, such as, sodium carbonate or sodium hydride, by use of no solvent or in a solvent, for example, .
21~3143 ketones, such as, acetone or ethyl methyl ketone, aromatic hydrocarbones, such as, benzene or toluene, ethers, such as, diethyl ether, tetrahydrofuran or dioxane, acetic esters, such as, ethyl acetate or isobutyl acetate, or in an aprotic polar solvent, such as, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidone.
A compound of the general formula (II) which is a starting material of the foregoing reaction can be prepared, for example, according to the following reaction formula from a compound of the following general formula (III) which are prepared according to the method described in Japanese First (unexamined) Patent Publication No.
50-157360 or the like.
o R 2 (III) ~
oR2 aluminum lithium hydride ~
(II) ~ N H
wherein pl and R2 are as defined before.
Preparation Method 2 When A is O S
Il 1~
- C - or - C -and Y represents -0-, -S-, -0-N=CH- or -NR5 - (R5 is as defined before), a compound of the following general formula (V) can also be prepared according to the following method:
o R 2 ~ x2 + R 3 - Y - H
/ \ 11 (IV) ~ N - C - C 1 o R 2 base ~ \ x2 r~ 11 ( V ) ~ N - C - Y - R 3 wherein Rl, R2, R3 and Y are as defined before, and x2 represents oxygen or sulfur.
The reaction is performed at a temperature range from 0 to 1500C
in the presence of organic base, such as, triethylamine, pyridine or N,N-diethylaniline or inorganic base, such as, sodium carbonate or sodium hydride, by use of no solvent or in a solvent, for example, ketones, such as, acetone or ethyl methyl ketone, aromatic hydrocarbones, such as, benzene or toluene, ethers, such as, diethyl ether, tetrahydrofuran or dioxane, acetic esters, such as, ethyl acetate or isobutyl acetate, or in an aprotic polar solvent, such as, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidone.
A compound of the foregoing general formula (IV) which is a starting material of the foregoing reaction can be prepared according to the following reaction formula from the starting material (II) in the preparation method 1.
21431~3 o R2 R 1 0 l x2 ~ C I - I - C 1 (II) ~ N H -o R 2 ~ x2 r~ 11 (IV) ~ N - C - C 1 wherein R', R2 and x2 are as defined before.
When the compound of the present invention is used as a treating medicament, the compound is dosed single or in combination with a pharmaceutically acceptable carrier. A composition of the carrier is determined based on solubility of the compound, chemical property of the compound, dosage route, dosage schedule and so on.
For example, the compound may be oral-dosed in the form of a granule medicine, a powder medicine, a tablet, a hard capsule medicine, a soft capsule medicine, a sirup medicine, an emulsion medicine, a suspended medicine or a liquid medicine, or may be intravenous-dosed, intramuscular-dosed or subcutaneous-dosed in the form of an injection medicine.
The compound may be powdered for injection and prepared to be used when necessary. The compound of the present invention may be used with pharmaceutical organic or inorganic and solid or liquid carrier or diluent which is suitable for oral, non-oral, throu~h-body or local dosing. As a forming agent to be used when producing the solid medicine, for example, lactose, sucrose, startch, talc, cellulose or dextrin may be used. The liquefied medicines for oral dosing, that is, the emulsion medicine, the sirup medicine, the suspended medicine, the -liquid medicine and the like, include the generally used inert diluent, such as, water or vegetable oil. These medicines can contain, other than the inert diluent, an auxiliary agent, such as, a wetting agent, a suspension assisting agent, a sweet agent, an aromatic, a coloring agent or a preserving agent. The liquefied medicine may be contained in a capsule made of a material, such as, gelatin which can be disintegrated in the body. As a solvent or a suspending agent to be used in the course of producing the medicine for non-oral dosing, such as, the medicine for injection, for example, water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate or lecithin can be enumerated. The known method can be used for making up the medicine.
When the compound of the present invention is used for oral dosing, a clinical dosing amount is, in general, O.Olmg to 1000mg per day, and preferably 0.01mg to 100mg, in case of an adult. It is naturally further preferable to properly increase or decrease a dosage amount depending on age, the condition of disease, the condition of patient, presence or absence of simultaneous dosing and so on. In case of the compound of the present invention, the foregoing dosing amount per day may be divided into two or three and dosed with proper intervals, or intermittent dosing may also be allowed.
On the other hand, when using the compound of the present invention as the injection medicine, it is preferable that a one-time dosage amount of 0.001mg to 100mg be continuously or intermittently dosed in case of an adult.
[Embodiment]
Hereinbelow, the present invention will be described in detail in terms of embodiments and test examples. The present invention is not limited to those embodiments and tests.
Embodiment 1 Preparation of 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethylaminocarbonyl) pyrrolidine (Compound No. 22 in Table 1):
216mg of 3-(aminomethyl) pyridine and 202mg of triethylamine were dissoved in 5ml of tetrahydrofuran. During agitation at a cold temperature, a solution obtained by dissolving 545mg of l-chloroformyl-3-(3-cyclopentyloxy-4-methoxyphenyl) pyrrolidine in 3ml of tetrahydrofuran was added in drops. After dropping, agitation was continued for 6 hours at a room temperature. Thereafter, the agitated solution was poured into ice water and then extracted with ethyl acetate. After organic layers were cleaned by water and dried over magnesium sulfate, it was concentrated under a reduced pressure. The residue was purified by means of the silica gel column chromatography to obtain 432mg of Compound No. 22 in Table 1.
Embodiment 2 Preparation of 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(ethoxycarbonyl) pyrrolidine (Compound No. 4 in Table 1):
460mg of 3-(3-cyclopentyloxy-4-methoxyphenyl) pyrrolidine and 214mg of triethylamine were dissoved in 15ml of dichloromethane and cooled in an ice bath. During agitation, 229mg of ethyl chloroformate was added in drops. After dropping, agitation was continued for 1 hour at a room temperature. Thereafter, the agitated solution was poured into ice water and then extracted with dichloromethane. After organic layers were cleaned by water and dried over magnesium sulfate, it was concentrated under a reduced pressure. The residue was purified by means of the silica gel column chromatography to obtain 92mg of Compound No. 4 in Table 1.
Embodiment 3 Compounds shown in Table 1 were synthesized according to the methods in Embodiments 1 and 2.
oR2 Table 1 compound R 1 R 2 - A - Y - R 3 physical No. properties O oily 1 M e ~ 11 matter - C - O B u t / O oily 2 M e ~ 11 matter - C - B u t O oily 3M e _~ 11 A matter \ J --C - O C H 2 ~
o oily 4M e ~ 11 matter \~ -C-OE t O oily M e ~ 11 matter \ ~ - C--C H 2 B u t O oily 6 M e / ¦ 11 matter \~ -C-OB un O oily 7 Me ~ -e~ matter O o oily 8 Me ~ I 11 matter \~ --C--O B u t 9 Me ~ 11 oily ~ - C ~ matter N
21~3143 Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physical No. properties Me ~ 11 oily - C - C H 2 ~ matter O m p 11 M e ~ ll H 125-126C
\~ --C--N--B u t O oily 12 M e ~ ll matter \ / - C - N M e 2 13 M e ~ 11 oi ly - C - O C H 2 ~ matter - C - O C H 2 ~ m p 14 M e ~ N 148-149C
M e ~ S O 3 H
M e _~ m p ~ - C - O C H 2 ~ H C l 108-114C
o 16 M e O - C - O C H 2 ~ 14P2-144C
o ~ ll A oily 17 M e ~ C O C H 2 ~ N~ matter - 21~3143 Table 1 (Continued) compound R I R 2 - A - Y - R 3 physical No. properties 18 M e ~ 11 A amorphous - C - O C H 2 N -~ O solid 19 M e ~ 11 A oi ly - C - O C H 2 ~ N matter Me ~ -S2 ~ matter 21 M e ~ 1l N oi 1Y
- C ~ ~ matter 22 Me O 11 m p- C - N H C H 2 ~ 129-130C
23 M e ~ 11 oily - C - O ~ matter 24 M e ~ 11 N oily - C - O C H 2 ~ matter o ~ ll A oily Me ~ -C-O~ ~ matter o ~o o ~ oi 1Y
26 M e ~ 11 N =,~ matter \ ~ --C--O C H
' 21431~3 Table 1 (Continued) compound R I R 2 - A - Y - R 3 physical No. properties 21 M e ~ N ~ M e oily ~ - C - O C H 2 ~ matter o 28 M e ~ 11 ~c==~ oily - C - O ~ N matter O oily 29 M e ~ 11 matter \ ~ - C - O C H 2 C H 2 N M e 2 oily M e ~ 11 matter '~,-' --C--O C H 2 C H 2 O H
~ oily 31 M e/ 1 11 matter - P (O E t) 2 O O M e oily O M e 33 M e ~ 11 1 A oily ~ - C - N - C H 2 ~ N~ matter 34 M e ~ O ~ N oily ll ~ matter - C - N ~
M eM e 11 A oily - C - O C H 2 ~ ~ matter 21~31~3 -Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physical No. properties 36 M e ~ 11 N oily ~ - C - O C H 2 C H 2 ~ matter o ~ 11 ~c==~ oily 37 M e ~ - C - O C H 2 ~ N matter O
38 M e ~ 11 A oily ~ - C - O C H 2 ~ ~-C 1 matter 39M e _ O 11 N oily - C - O - N = C H ~ matter M e O S oily - C - O C H 2 ~ matter 41 M e ~ N oily - C - O C H 2 ~ ~ matter N
42M e _ ~ 11 A oily - C - O C H 2~ matter N - N
43 M e ~ 11 N oily - C - O C H 2 ~ ~ matter Table 1 (Continued) compound Rl R2 - A - Y - R3 physical No. properties M e ~ oily 44M e ~ - C - O C H 2 ~ N ,N matter M e 45M e ~ oily - C - O C H2 ~ matter O ~ oily 46M e / ¦ ll N==~ matter \ / - C--O C H2 ~ N/~
Hereinbelow, NMR spectra are shown for the following compounds in the form of amorphous solid and oily matter, wherein the compounds are identified by Compound No. in Table 1.
-No.l 'HNMR(CDCl3)~ppm:1. 48(s,9H),1.53-1.
69 (m, 2H),1.73-2.00(m, 7H),2.14-2.28 (m lH),3.16-3.86 (m, 5H),3.83(s,3H),4.70 -4.81(m, lH),6.73-6.85(m,3H) No.2 'HNMR(CDCl3)~ppm:1. 28(s,9H),1.50-1.
68 (m, 2H),1.73-2.04(m,7H),2.13-2.33 (m lH),3.16-4.10(m, 5H),3.83(s,3H),4.71 -4.80(m, lH),6.71-6.85 (m, 3H) No.3 IHNMR(CDCl 3 ) ~ppm:l. 52-1.65(m,2H),l.
76-2.05 (m, 7H),2.18-2.36(m,lH),3.24-3 .92 (m, 5H),3.82(s,3H),4.72-4.79(m, 1 H) ,5.16(s,2H),6.74-6.83 (m, 3H),7.24-7.3 8(m,5H) No.4 'HNMR(CDCl 3 )~ppm:1.24-1.31(m, 3H),l.
54-1.70(m, 2H),1.74-2.04(m,7H),2.18-2 .32 (m, 1 H),3.22-3.90(m, 5H),3.83(s,3H) ,4.12-4.22 (m, 2H),4.77 (m, lH),6.74-6.8 4(m,3H) No.5 'HNMR(CDCl 3 ) ~ppm:1.08(brs,9H),1.54-2.38(m,1OH),2.21(brs,2H),3.22-4.06 (m ,5H),3.83(s,3H),4.70-4.80(m,lH),6.75 -6.81(m, 3H) No.6 'HNMR(CDCl3)~ppm:0.90-0.98(m,3H),l.
~1~3~
34-2.04(m,13H).2.18-2.32(m,1H).3.24-3.92(m,5H).3.82(s,3H),4.08-4.13(m,2H
).4.76(m,1H).6.74-6.83(s.3H) No.7 'HNMR(CDCI 3 ) ~ppm:1.56-1.70(m.2H).l.
76-2.42(m.8H).3.24-3.94(m.5H).3.83(b rs.3H).4.70-4.80(m.1H).6.71-6.82( m, 3 H).7.38-7.43(m,3H).7.54--7.56 (m, 2H) No.8 'HNMR(CDCI 3 ) ~ppm:1.48(s,9H),1.80-2.
28 (m, 4H),3.15-4.09(m, 9 H),3.84(s.3H), 4.89-5.00(m, 1 H).6.73(brs,1H),6.84(br s,2H) No.9 'HNMR(CDCl 3 ) ~ppm:l. 56-2.44 (m, 1 OH),3 .28-4.16 (m, 5H),3.82 and 3.84(a pair of s,3H),4.72-4.80(m, 1 H),6.70-6.83 (m ,3H),7.32-7.40(m,1H),7.86-7.92(m,1H) ,8.64-8.69(m, 1 H).8.81(m, 1 H) No.10 'HNMR(CDCI 3 ) ~ppm:1.56-2.42 (m, I OH),3 .26-4.08(m,5H).3.66(brs.2H),3.83(brs 3H),4.75 (m, I H),6.72-6.84(m,3H),7.24 -7.30(m,1H),7.68-7.74 (m, 1 H).8.50-8.5 2 (m, 2H) No.12 'HNMR(CDCI 3 ) ~ppm:l. 53-1.68(m,2H),I.
75-2.00(m,7H),2.15-2.28(m.lH).2.85(s .6H).3.18-3.31(m,1H).3.39(t.1H,J=9Hz 21431~3 ),3.46--3.61(m, 2H),3.70(d--d,lH,J=7 an d 9Hz),3.83(s,3H),4.71-4.80(m, lH),6.
74-6.84(m,3H) No.13 'HNMR(CDCI a ) ~p pm:l. 51-1.70(m,2H),l.
75-2.04(m,7H),2.18-2.34(m,1H),3.23-3 .53(m,3H),3.58-3.96 (m, 2H),3.83(s,3H) ,4.68-4.80(m, lH),5.18(s,2H),6.70-6.8 4 (m, 3H),7.26-7.35 (m, lH),7.73 (m, lH),8 .57 (m, lH),8.65 (m, lH) No.17 IHNMR(CDCl 3 ) ~ppm l. 51-1.70(m,2H),l.
75-2.09(m, 7H),2.20-2.35(m,1H),3.25-3 53 (m, 3H),3.63-3.75 (m, lH),3.80-3.93( m,lH),3.83(s,3H),4.71-4.81(m, lH),5.1 3(brs,2H),6.70-6.86(m,3H),7.27 (m, 2H) ,8.16 (m, lH),8.28 (m, lH) No.18 ~HNMR(CDCl 3 ) ~ippm:l. 54-2.08 (m, 9H),2.
22-2.36 (m, lH),3.28-3.92(m,5H),3.83(s ,3H),4.76 (m, lH),5.12(brs,2H),6.75-6.
84 (m, 3H),7.27-7.32 (m, 2H),8.17-8.21(m ,2H) No.l9 'HNMR(CDCl 3 ) ~ppm:1.56-2.12(m,9H),2.
24-2.36 (m, lH),3.30-3.90(m,5H),3.83(s ,3H),4.77 (m, lH),5.19(brs,2H),6.76-6.
86 (m, 3H),7.26-7.30(m, 2H),8.57-8.61(m ,2H) No.20 'HNMR(CDCl 3 ) ~ppm:1.56-2.06 (m, 9H),2.
14-2.28 (m, lH),3.16-3.90(m, 5H),3.81(s 3H),4.68-4.76 (m, lH),6.61-6.78 (m, 3H) ,7.48-7.56 (m, lH),8.13-8.16 (m, lH),8.9 4(brs,1H),9.10(brs,lH) No.21 'HNMR(CDCI 3 ) ~ppm:l. 56-2.16 (m, 9 H),2.
30-2.40(m,lH),3.30-3.48 (m, lH),3.64-4 .26 (m, 4H),3.83(brs,3H),4.74-4.80(m,1 H),6.77-6.83(m,3H)-,8.52-8.56(m,lH),8 .62-8.66(m,1H),9.17(s,1H) No.23 IHNMR(CDCl 3 ) ~ppm:1.56-2.18(m,9H),2.
26-2.42(m,lH),3.34-4.16(m,5H),3.83(s ,3H),4.72-4.80(m,1H),6.78-6.88(m,3H) ,7.32(m,1H),7.55-7.60(m,1H),8.47(m,2 H) No.24 'HNMR(CDCl 3 ) ~ppm:l. 50-1.70(m, 2H),l.
73-2.04 (m, 7H),2.20-2.35(m,1H),3.25-3 .59(m,3H),3.66-3.78 (m, lH),3.83(s,3H) ,3.86-3.96(m,1H),4.70-4.79(m, lH),5.2 8(brs,2H),6.71-6.84 (m, 3H),7.16-7.26( m, lH),7.39(t,1H,J=7Hz),7.65-7.74 (m, 1 H),8.58 (m, lH),8.65 (m, lH) No.25 'HNMR(CDCl 3 ) ~ppm:1.56-2.16(m,9H),2.
28-2.44 (m, lH),3.34-4.06 (m, 5H),3.84(s 21931~3 ,3H),4.74-4.80(m,1H),6.77-6.83(m,3H) ,7.23-7.27 (m, 2H),8.06-8.09(m,1H),8.1 9(s,lH) No.26 IHNMR(CDCI 3 ) ~ppm:1.50-1.70(m,2H)1.7 5-2.10(m,7H),2.22-2.40(m,1H),3.30-3.
62 (m, 3H),3.68-3.83 (m, lH),3.84(s,3H), 3.89-4.00(m, lH),4.70-4.81(m, lH),5.44 (brs,2H),6.74-6.86 (m, 3H),7.20-7.35(m 2H~,7.36-7.45 (m, 1 H),8.25 (m, 1 H) No.27(diastereo mix ture) IHNMR(CDCl 3 ) ~ ppm:l. 52-2.40(m, 1 7H),2 .27 and 2.29(a pair of s,3H),2.78-2.
94(m,2H),3.24-4.08 (m, 7H),3.83(s,3H), 4.72-4.80(m,1H),6.75-6.86 (m, 3H) No.28 IHNMR(CDCI 3 ) ~ppm:l. 56-1.72(m,2H),l.
76-1.94 (m, 6H),2.04-2.16 (m, 1 H),2.33-2 .42(m,1H),3.34-3.93 (m, 5H),3.83(s,3H) ,4.73-4.80(m,1H),6.32-6.38(m,2H),6.7 5-6.86 (m, 3H),7.72-7.77(m,2H) No.29 IHNMR(CDCl 3 ) ~ppm:1.51-1.69(m,2H),l.
74-2.01(m,7H),2.15-2.30(m,1H),2.29(s ,3H),2.31(s,3H),2.60(m, 2H),3.22-3.50 (m,3H),3.57-3.72(m,1H),3.75-3.91(m,1 H),3.82(s,3H),4.22(t,2H,J=5Hz),4.70-4.80(m,1H),6.71-6.84(m,3H) No.30 21431~3 IHNMR(CDCl 3 ) ~ippm:l. 51-1. 69 (m, 2H).l.
74-2.0 5 (m, 7H).2.19-2.34 (m, lH).2.80(b rs.lH).3.23-3.74 (m, 7H),3.83(s,3H),4.
23--4.31(m.2H).4.70--4. 81 (m, lH). 6. 72--6 85 (m, 3H) No.31 - IHNMR(CDCl 3 ) ~ppm:l. 30-1.37 (m, 6H).l.
5 4-1. 6 8 (m, 2H).1.78-2.04 (m, 7H).2.20-2 .32 (m, lH).3.10-3.1 8 (m, lH).3.24-3. 50 ( m, 3H).3. 6 0-3. 68 (m, lH),3. 8 3(s.3H).4.0 0-4.1 6 (m, 4H).4.72-4.80(m, lH).6.7 5-6 83 (m, 3H) No.32 IHNMR(CDCI 3 ) ~ppm:l. 56-2.06 (m, 9H).2.
18-2.30(m, lH).2.72-2.9 6 (m, 2H).3.24-3 .92 (m, 7H).3. 8 3(s.3H).3. 8 5(s.3H).3. 8 6 (s.3H).4.40(s.2H).4.72-4. 80 (m, lH),6.
59(s.1H).6.62(s.1H).6.77-6. 86 (s, 3H) No.33 IHNMR(CDCl 3 ) (~ppm:l. 56-2.06 (m, 9H),2.
16-2.32 (m, lH).2. 81 (s, 3H).3.22-3.36 (m .lH).3.43(t.lH.J=9Hz).3.54-3.60(m, 2H
).3.72-3. 81 (m, lH).3.83(s.3H).4.43(d.
lH,J=12Hz).4. 5 O(d.lH.J=12Hz),4.72--4.
80(m, lH).6.7 5--6. 84 (m, 3H),7.2 5--7.30(m lH).7. 6 8-7.71(m, lH).8.52-8.5 6 (m, 2H) No.34(diastereo m ixture) 'HNMR(CDCl 3 ) ~p pm:l. 5 6- 2.08 (m, lOH).2 .18-2.36 (m, 2H).3.20-3.94(m.1OH).3.83 (s,3H),4.72-4.80(m,1H),6.76-6.84(m,3 H),7.16-7.19(m, 2H),8.53-8.55 (m, 2H) No.35 IHNMR(CDCl3)~ppm:1. 90- 2.10(m, 1 H),2.
19-2.33 (m, 1 H),3.24-3.51(m, 3H),3.60-3 . 9S (m, 2H),3.87(s,6H),5.18(brs.2H),6.
70-6.86 (m,- 3H),7.27-7.34 (m, 1 H),7.68-7 .76 (m, 1 H),8.57 (m, 1 H),8.65(m,1H) No.36 'HNMR(CDCl3)~ppm:1. 56-2.06 (m, 9H),2.
16-2.28 (m, lH),3.12-3.88(m,7H),3.83(s 3H),4.48(t,2H,J=7Hz),4.75 (m, 1 Hj,6.7 2-6.83 (m, 3H),7.10-7.24 (m, 2H),7.54-7.
64 (m, 1 H),8.54(m,1H) No.37 'HNMR(CDCl3) ôppm:l. 56-2.12 (m, 9H),2.
22-2.38 (m, 1 H),3.50-3.58 (m, 3H),3.68-3 94 (m, 2H),3.83(s,3H),4.77 (m, 1 H),5.16 (brs,2H),6.76-6.85(m,3H),7.12-7.21(m lH),7.31-7.33 (m, 1 H),8.34-8.38 (m, 1 H) No.38 IHNMR(CDCl3)~ppm:1. 51-1. 68 (m, 2H),l.
73-2.04 (m, 7H),2.19-2.33 (m, 1 H),3.23-3 52(m,3H),3.57-3.92 (m, 2H),3.83(s,3H) 4.70-4.80(m, lH), 5.15(brs,2H),6.70-6 .84(m,3H),7.29-7.36( m, 1 H),7.67-7.74( m, 1 H),8.42 (m, lH) No.39 HNMR(CDCl3)~ppm:1.50-1.71(m,2H),l.
21431~3 74-2.11(m,7H),2.23-2.40(m, lH),3.30-3 .64 (m, 3H),3.70-3.85 (m, lH),3.84(s,3H) ,3.90-4.05(m,1H),4.71-4.83 (m, lH),6.7 3-6.85 (m, 3H),7.33(t,lH,J=9Hz),7.76(t ,lH,J=9Hz),8.14(d,lH,J=9Hz),8.43(d,1 H,J=9Hz),8.64(brs,lH) No.40 IHNMR(CDCl3)~ ppm:l. 56-2.16 (m, 9H),2.
28-2.42 (m, lH),3.32-4.28 (m, 5H),3.83(b rs,3H),4.72-4.78 (m, lH),5.56 and 5.57 (a pair of s,2H),6.71-6.84 (m, 3H),7.2 6-7.34 (m, lH),7.72-7.76 (m, lH),8.54-8.
62 (m, lH),8.65-8.69(m,1H) No.41 IHNMR(CDCl3) ôppm:l. 56-2.18 (m, 9H),2.
32-2.42(m,1H),3.32-3.46 (m, lH),3.54-3 .66 (m, lH),3.72-3.90(m,2H),3.83(s,3H) 3.94-4.06 (m, lH),4.48(brs,1H),4.60(s 2H),4.72-4.80(m, lH)6.75-6.85 (m, 3H), 7.28-7.30(m,lH),8.02(s,lH) No.42 IHNMR(CDCl3)0ppm:1.56-2.08 (m, 9H),2.
22-2.36(m,lH),3.26-3.56 (m, 3H),3.66-3 .96 (m, 2H),3.83(s,3H),4.72-4.80(m, lH) ,5.50 and 5.51(a pair of s,2H),6.75-6.84 (m, 3H),7.46--7.53(m,1H),7.58-7.66 (m,lH),9.14-9.16(m,1H) No.43 'HNMR(cDcl3)~ppm:l. 56-2.10(m, 9H),2.
-20-2.36 (m, lH),3.28-3.56 (m,3H),3.70-3 .96 (m,2H),3.83 (s,3H),4.77 (m, lH),5.32 and 5.33 (a pair of s,2H),6.75-6.84 ( m,3H),8.53-8.56 (m,2H),8.70-8.71 (m, lH
) No.44 'HNMR (CDCl 3 ) ~p pm:l.50-1.70 (m,2H),1.
74-2.04 (m,7H),2.18-2.40 (m, lH),2.24 (b rs,3H),3.22-3.92 (m,5H),3.82 (brs,6H), 4.70-4.80 (m, lH),5.10 (brs,2H),6.08 (br s, lH),6.69-6.84 (m,3H) No.45 'HNMR (CDCI 3 ) ~ppm:1.50-1.69 (m,2H),1.
75-2.03 (m,7H),2.18-2.30 (m, lH),3.23-3 .93 (m,5H),3.82 (s,3H),4.70-4.80 (m, lH) ,5.02 (brs,2H),6.46 (m, lH),6.70-6.84 (m ,3H),7.39 (m, lH),7.48 (m, lH) No.46 'HNMR (CDCI 3 ) ~ppm:1.56-2.12 (m,9H),2.
22-2.38 (m, lH),3.30-3.58 (m,3H),3.68-3 .96 (m,2H),3.84 (s,3H),4.74-4.80 (m, lH) ,5.27 (brs,2H),6.76-6.85 (m,3H),8.02 (m , lH),8.17-8.19 (m, lH),8.41-8.43 (m, lH) 21~31~3 -Embodiment 4 Preparation of (+)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine and (-)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine:
145mg of (+ )-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine (Compound No. 13 in Table 1) was separated with HPLC (eluent: ethanol/hexane = 10/90) using the optical isomer separation column CHIRALPAKAS (Daicel xxx) to obtain (+)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolldine (Compound No. 47) 64mg [ a ]D25 = +22.3 (cO.91, methanol), and (-)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyrid ylmethoxycarbonyl) pyrrolidine (Compound No. 48) 61mg [ a ]D25 = -23.7 (c1.02, methanol).
Embodiment 5 Compounds shown in Table 1 (shown hereinbelow) were synthesized according to the methods in Embodiments 1 and 2.
- 21~314~
Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physical No. properties o 49M e _ ~ ll / /7- N \ oily ~ ~ 2 ~ )2 matter o 50 M e ~ - C - N ~ matter 51M e _ ~ ll /7-~ oily ~ - C S C H 2 ~ matter o 52 M e ~ ll /r ~ oily \- C C H 2 C H 2 ~ matter 53 M e ~ 11 /r ~\ oily - C N H C H 2 ~ \~- B u n matter O oily 54 M e ~ 11 matter \~-' - C O C H 2 C H 2 S 2 M e o ~ 0 11 M e _/ 11 C C H 3 oily - C N / ~ matter N
o 56 M e ~ 11 N -~ oily ~- C N H C H 2 ~ matter o 57 M e ~ ll ~7-~ oily - C N H C H 2 C H 2 ~ N ~ matter Table 1 (Continued) compound R 1 R 2 - A - Y - R 3 physica1 No. properties 58 M e ~ - C N O M e 12P0-123C
o 59 M e ~ ll /r ~ oily ~ - C N H ~ ~ matter M e ~ - C N H C H 2 C H 2 ~ ~ matYter 61M e ~ 11 ~ m p 62M e ~ 2 2~ matter M e 63M e _ ~ 11 ~ amorphous - ~ - C N H C H 2 ~ S~ solid Il ~ amorphous 64M e ~ - C N H ~ N solid In Table 1, Me represents methyl, Et ethyl, Bun n-butyl and But tert-butyl.
- 21~314~
-No.49 'HNMR(CDCl 3 ) ~ppm:l. 50-2.10(m, 9H).2.
20-2.38 (m, 1 H),3.2-3.7 (m, 4H),3.8(m,1H
),3.82(s,3H),4.23-4.57 (m, 4H),4.60-4.
83(m,1H),6.63-6.93 (m, 3H),7.20-7.40(m 2H),7.57-7.76 (m, 2H),8.40-8.68 (m, 4H) No.50 IHNMR(CDCl 3 ) l~p pm:l. 49-2.10 (m, 9H),2.
20-2.36 (m, lH),2.9-3.8 (m, 9H),3.83(s,3 H),4.73(s,2H),4.70-4.80(m, 1 H),6.70-6 85 (m, 3H),6.80(dd,1H),7.41(d,1H),8.4 3(d,1H) No.51 IHNMR(CDCl 3 ) ~ppm:l. 49-1.71(m, 2H),l.
74-2.09(m, 7H),2.20-2.36 (m, 1 H),3.2-4.
1 (m, 5H),3.82(s,3H),4.20(s,2H),4.69-4 79(m,1H),6.69-6.84 (m, 3H),7.19-7.41( m,5H) No.52 IHNMR(CDCl 3 ) ~ppm:1.53-1.70(m,2H),l.
75-2.08 (m, 7H).2.20-2.38 (m, lH).3.2-4.
1 (m, 5H),3.82(s,3H),4.13 (m, 2H),4.65 (m ,2H),4.70-4.80(m, 1 H),6.70-6.85 (m, 3H) ,7.25-7.43(m,5H) No.53 IHNMR(CDCl 3 ) ~ppm:O. 9 4(t,3H),1.39(m, 2H),1.51-2.09(m,1lH),2.23-2.35(m,lH) ,2.77(t,2H),3.25-3.48(m,3H),3.55-3.6 6 (m, 1 H),3.8(m,1H),3.83(s,3H),4.44(d, -2H). 4. 53(t,lH), 4. 6 9 - 4. 79(m, lH), 6. 73-6. 8 5 (m, 3H),7.11(d,1H),7. 6 O(dd,lH), 8.
4 4 (d,lH) No.5 4 'HNMR(CDC1 3 ) ~p p m : 1. 53-1.70(m, 2H),1.
75-2.0 8 (m, 7H),2.19-2.35 (m, lH),3.00(m ,3H),3.20-3.51(m,5H),3.55-3.90(m, 2H) 3. 8 3(s,3H), 4. 57(m,2H), 4. 70--4. 81 (m,l H). 6. 70- 6. 8 5(m,3H) No.55 'HNMR(CDCl 3 ) ~ippm:1.52-1. 74 (m,2H),l.
75-2.07(m,7H),2.17(s, 3 H),2.20-2. 3 8 (m lH), 3. 1 - 3. 9 (m,5H), 3. 8 3 (s, 3 H), 4. 6 3 - 4 9 3 (m, 3 H), 6. 5 4 - 6. 84(m,3H),7.27 (m, lH) 7.75 (m, lH),8. 4 7-8. 6 3 (m, 2H) No.5 6 IHNMR(CDC1 3 ) ~p p m : 1. 4 7-1.7 4 (m, 2H),1.
7 4 - 2.10(m, 7H),2.18-2.37 (m, lH),3.1 8 - 3 .53 (m, 3H),3.58-3.94 (m, 2H),3.80(s,3H) , 4. 5 4 (d,2H), 4. 7 0 - 4. 80(m, lH),5.8 4 (t,l H), 6. 73-6.83 (m, 3 H),7.15 (m, lH),7. 3 O(m ,lH),7.62(m,1H),8.49(m,1H) No.57 'HNMR(CDCl 3 ) ~p pm:l.50-1.70(m,2H),l.
72-2.04(m,7H),2.18-2. 3 4 (m, lH), 3. Ol(t 2H), 3. 22- 3. 85 (m, 7H), 3. 8 3 (s, 3 H),4.68 -4.79(m, lH),5. 34 ( t,lH), 6. 73--6. 83(m, 3 H), 7. 08-7.20(m, 2H),7.57-7.6 4 (m, lH),8 . 5 0 (m, lH) No.59 IHNMR(CDCl 3 ) ~ppm:l. 47--2.15 (m, 9H),2.
22-2.42 (m, lH),3.28-4.03 (m, 5H),3.83(s 3H),4.70--4.80(m, 1 H),6.61(bs,1H),6.7 5--6.85 (m, 3H),7.22 (m, 1 H),8.09(m,1H),8 .24(m,1H),8.48(m,1H) No.60 'HNMR(CDCl 3 ) ~ppm:l. 48-1.70(m, 2H),l.
70-2.05 (m, 7H),2.16-2.33 (m, lH),2.98(t 2H),3.16-3.33 (m, 3H),3.45-3.75 (m, 4H) 3.81(s,3H),4.37(t,1H),4.70-4.80(m, H),6.65-6.95 (m, 3H),7.00(m, 1 H),7.06-7 23 (m, 2H),7.35 (m, 1 H),7.62 (m, 1 H),8.67 (bs,lH) No.62 IHNMR(CDCl 3 ) ôppm:l. 50-1.70 (m, 2H),1.
75-2.05 (m, 7H),2.18-2.35 (m, lH),2.81(t 2H),3.23-3.55 (m, 6H),3.59(s,3H),3.70 -3.87 (m, 1 H),3.83(s,3H),4.45(t,1H),4.
70-4.80(m, 1 H),5.92 (m, 1 H),6.05 (m, 1 H), 6.57(m,1H),6.73-6.83(m,3H) No.63 IHNMR(CDCI 3 ) ôppm:l. 52-1.70 (m, 2H),l.
74--2.07(m,7H),2.18-2.39(m, 1 H),3.3-3.
8 (m, 5H),3.83(s,3H),4.56(m,1H),4.63(d ,2H),4.70-4.80(m, 1 H),6.73-6.83(m,3H) ,6.92-7.00(m, 2H),7.22 (m, lH) No.64 'HNMR(CDCl 3 ) ~ppm:1.53-1.72(m,2H),l.
21431~3 7 5 - 2. 2 3 ( m, 7 H ) , 2. 3 0 - 2. 4 7 ( m, 1 H ) , 3. 4 7 - 3 6 6 ( m, 3 H ) , 3. 7 9 ( m, 1 H ) , 3. 8 4 ( s, 3 H ) , 3. 9 8 ( m, 1 H ) , 4. 7 3 - 4. 8 3 ( m, 1 H ) , 6. 2 7 ( b s, 1 H ) , 6 7 8 - 6. 8 6 ( m, 3 H ) , 8. 4 8 ( s, 2 H ) Hereinbelow, compounds which can be synthesized according to the methods of Embodiments 1 and 2 will be shown in Table 2.
.
o~
Me O
`~
Table 2 compound No. Y n B
6 6 -O- 2 ~
6 7 -O- 2 ~>
6 8 --O-- 2 ~N
6 9 --O-- 2 ~N > O
7 0 --NH - 1 ~N
7 1 --NH - 2 ~
7 2 --NH-- 2 ~N
7 3 -NMe- 1 21~31~
Table 2 (Continued) compound No. Y n B
74 -NMe- 1 ~N
75 -NMe- 2 ~
76 -NMe- 2 ~ ) 77 -NMe- 2 ~N
78 -O- 1 ~ OMe 79 -O- 2 ~ OMe -O- 1 ~ OEt 81 --O-- 2 ~ O Et 8 2 - O - 1 ~ O P r 83 -O- 2 ~ O P r 84 -O- 1 ~O B u -O- 2 ~ O B u N
-Table 2 (Continued) compound No. Y n B
86 -NH- 1 ~ OMe N
87 -NH- 2 ~ OMe N
88 -NH- 1 ~ OEt N
89 --NH- 2 ~ O Et N
-NH- 1 ~ OPr N
91 -NH- 2 ~ O P r N
21431~3 7 5 - 2. 2 3 ( m, 7 H ) , 2. 3 0 - 2. 4 7 ( m, 1 H ) , 3. 4 7 - 3 6 6 ( m, 3 H ) , 3. 7 9 ( m, 1 H ) , 3. 8 4 ( s, 3 H ) , 3. 9 8 ( m, 1 H ) , 4. 7 3 - 4. 8 3 ( m, 1 H ) , 6. 2 7 ( b s, 1 H ) , 6 7 8 - 6. 8 6 ( m, 3 H ) , 8. 4 8 ( s, 2 H ) Hereinbelow, compounds which can be synthesized according to the methods of Embodiments 1 and 2 will be shown in Table 2.
.
o~
Me O
`~
Table 2 compound No. Y n B
6 6 -O- 2 ~
6 7 -O- 2 ~>
6 8 --O-- 2 ~N
6 9 --O-- 2 ~N > O
7 0 --NH - 1 ~N
7 1 --NH - 2 ~
7 2 --NH-- 2 ~N
7 3 -NMe- 1 21~31~
Table 2 (Continued) compound No. Y n B
74 -NMe- 1 ~N
75 -NMe- 2 ~
76 -NMe- 2 ~ ) 77 -NMe- 2 ~N
78 -O- 1 ~ OMe 79 -O- 2 ~ OMe -O- 1 ~ OEt 81 --O-- 2 ~ O Et 8 2 - O - 1 ~ O P r 83 -O- 2 ~ O P r 84 -O- 1 ~O B u -O- 2 ~ O B u N
-Table 2 (Continued) compound No. Y n B
86 -NH- 1 ~ OMe N
87 -NH- 2 ~ OMe N
88 -NH- 1 ~ OEt N
89 --NH- 2 ~ O Et N
-NH- 1 ~ OPr N
91 -NH- 2 ~ O P r N
9 2 --NH-- 1 ~ O B u 93 --NH--2 ~ O B u 94 -NMe- 1 ~ OMe N
-NMe- 2 ~ O M e N
96 -NMe- 1 ~ OEt N
97 -NMe- 2 ~ 9 O E t N
Table 2 (Continued) co~pound No. Y n B
98 -NMe- 1 ~ OPr N
99 -NMe- 2 ~ O P r N
100 -NMe- 1 ~ O B u N
101 -NMe- 2 ~ O B u N
N=N
103 -O- ~N
104 -O- 2 ~ ,N
N
~N3 107 _O_ 2 ~ 3 N
108 -O- 2 ~ 3 O
Table 2 (Continued) co~pound No. Y n B
, o g - o - 1 ~3 ~ N
1 1 0 - O - 2 ~3 o ~ N
N
1 1 2 - O - 2 ~-y ~
1 1 3 - O - 1 ~ N
1 1 4 - O - 2 ~ N
N=N
N=N
1 1 9 - N H - 1 ~ ,N
21g31g3 Table2 (Continued) compoundNo. Y n B
120 -NH- 2 ~ N
121 -NH- 1 ~3 122 -NH- 2 ~3 123 -NH- N~
124 -NH- N~
125 -NH- 1 ~ N
126 -NH- 2 ~ N
129 -NMe- 1 N=N
130 -NMe- 2 ~
131 -NMe- 1 ~,N
21431~3 ._ Table 2 (Continued) compound No. Y n B
1 3 2 -NMe- 2 ~\N
1 3 3 - NMe- 1 ~3 -1 3 4 -NMe- 2 ~ ~
N
135 -NMe- 1 136 -NMe- 2 ~ ~
1 3 7 -NMe- 1 ~ N
1 3 8 -NMe- 2 ~ N
N
139 -NMe- 1 140 -NMe- 2 ~ ~
In Table 2, Me represents methyl, Et ethyl, Pr propyl and Bu butyl.
21431~3 Embodiment 6 Preparation of Tablet:
1000g of well crushed 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine hydrochloride (Compound No. 15 in Table 1), 5900g of lactose, 2000g of crystal cellulose, 1000g of low-degree substitution hydroxypropylcellulose and 100g of magnesium stearate are well mixed so as to produce bare tablets containing 10mg of the foregoing compound in one tablet of 100mg using the direct tablet making method. By applying sugar-coating or film-coating to the bare tablets, the sugar-coated tablets or the film-coated tablets were produced.
Embodiment 7 Preparation of Capsule Medicine 1000g of well crushed 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine p-toluenesulfonate (Compound No. 14 in Table 1), 3000g of corn starch, 6900g of lactose, 1000g of crystal cellulose and 100g of magnesium stearate were mixed to produce capsule medicine containing 10mg of the foregoing compound in one capsule of 120mg.
Embodiment 8 Preparation of Inhalation Medicine 5g of well crushed 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethylaminocarbonyl) pyrrolidine (Compound No. 22 in Table 1), 10g of medium-chain saturated fatty acid triglyceride and 0.2g of (sorbitan xxx) were well mixed. Subsequently, a mixture of 15. 2mg was weighed into each aluminum container of 5ml for aerosol. Further, a mixture of freon 12 and 114, in the ratio of 1:1, of 84.8mg at a low temperature was filled into each container. Thereafter, an adaptor for metering 10.0ml per injection was attached to the container to produce inhalation medicine containing 5mg of the foregoing compound in one 21431~3 spray-type container of 5ml. For showing availability of the compounds of the present invention, the results of the pharmacological tests of the compounds will be given hereinbelow.
(roliplum xxx) in Table 3 is the compound represented by the foregoing structure as described in the foregoing Japanese First Patent Publication No. 50-157360. In, for example, Adv. Second Messenger Phosphoprotein Res., 22, 1 (1988), it is described to show specific inhibition to PDE IV.
Test 1 Action to Phosphodiesterase (PDE) IV Enzyme Activities Enzyme was partialy purified from human histiocytic lymphoma(U937) cytoplasm fraction by means of the Q-sepharose column according to the method of Nicholson and collaborators [Br. J.
Pharmacol., 97, 889 (1989)], and was reacted in a solution of 0.1mg/ml BSA (bovine serum albumin), 1mM EDTA (ethylenediaminetetra acetic acid), 5mM MgCl2 and 50mM Tris-buffer (pH 8.0) for 15 minutes at 30C
using 0.4 ~ M 3H-cAMP as substrate accodring to the method of Hidaka and collaborators [Biochem. Med., 10, 301 (1974)]. 3H-5'-AMP generated was separated by means of the cation exchange column, and the enzyme activity was determined by measuring a radioactivity amont.
A test compound was added. After incubations for 15 minutes at 30C, the substrate was added. Inhibition ratios were derived for respective concentrations assuming that the reaction without the test compound was 100%. By using the probit analysis, the concentration (IC50) showing the inhibition rate of 50% was derived. The results are shown in Table 3.
Table 3 compound No. PDE IV inhibitory activity IC50 (M) 1. Oxl o 8 3 6. 0 x 1 0~9 4 1. 1 x 1 o~8 6 6. 0 x 1 0~9 7 2. 0 x 1 o 8 8 1. 9 x 1 o~8 1 3 3. 3 x 1 0 9 1 7 2. 3 x 1 o 8 1 9 3. 8 x 1 0~9 2 3 1. 4 x 1 o 8 2 4 2. 3 x 1 0~9 2 6 8. 8 x 1 0~9 3 2 2. 5 x 1 o 8 3 6 1. 1 x 1 o 8 3 7 1. 9 x 1 o 8 3 8 2. 3 x 1 o~8 4 0 1. 0 x 1 o 8 4 2 8. 0 x 1 0~9 4 8 1. 1 x 1 0~9 roliplam 3. o x 1 0~7
-NMe- 2 ~ O M e N
96 -NMe- 1 ~ OEt N
97 -NMe- 2 ~ 9 O E t N
Table 2 (Continued) co~pound No. Y n B
98 -NMe- 1 ~ OPr N
99 -NMe- 2 ~ O P r N
100 -NMe- 1 ~ O B u N
101 -NMe- 2 ~ O B u N
N=N
103 -O- ~N
104 -O- 2 ~ ,N
N
~N3 107 _O_ 2 ~ 3 N
108 -O- 2 ~ 3 O
Table 2 (Continued) co~pound No. Y n B
, o g - o - 1 ~3 ~ N
1 1 0 - O - 2 ~3 o ~ N
N
1 1 2 - O - 2 ~-y ~
1 1 3 - O - 1 ~ N
1 1 4 - O - 2 ~ N
N=N
N=N
1 1 9 - N H - 1 ~ ,N
21g31g3 Table2 (Continued) compoundNo. Y n B
120 -NH- 2 ~ N
121 -NH- 1 ~3 122 -NH- 2 ~3 123 -NH- N~
124 -NH- N~
125 -NH- 1 ~ N
126 -NH- 2 ~ N
129 -NMe- 1 N=N
130 -NMe- 2 ~
131 -NMe- 1 ~,N
21431~3 ._ Table 2 (Continued) compound No. Y n B
1 3 2 -NMe- 2 ~\N
1 3 3 - NMe- 1 ~3 -1 3 4 -NMe- 2 ~ ~
N
135 -NMe- 1 136 -NMe- 2 ~ ~
1 3 7 -NMe- 1 ~ N
1 3 8 -NMe- 2 ~ N
N
139 -NMe- 1 140 -NMe- 2 ~ ~
In Table 2, Me represents methyl, Et ethyl, Pr propyl and Bu butyl.
21431~3 Embodiment 6 Preparation of Tablet:
1000g of well crushed 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine hydrochloride (Compound No. 15 in Table 1), 5900g of lactose, 2000g of crystal cellulose, 1000g of low-degree substitution hydroxypropylcellulose and 100g of magnesium stearate are well mixed so as to produce bare tablets containing 10mg of the foregoing compound in one tablet of 100mg using the direct tablet making method. By applying sugar-coating or film-coating to the bare tablets, the sugar-coated tablets or the film-coated tablets were produced.
Embodiment 7 Preparation of Capsule Medicine 1000g of well crushed 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethoxycarbonyl) pyrrolidine p-toluenesulfonate (Compound No. 14 in Table 1), 3000g of corn starch, 6900g of lactose, 1000g of crystal cellulose and 100g of magnesium stearate were mixed to produce capsule medicine containing 10mg of the foregoing compound in one capsule of 120mg.
Embodiment 8 Preparation of Inhalation Medicine 5g of well crushed 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-pyridylmethylaminocarbonyl) pyrrolidine (Compound No. 22 in Table 1), 10g of medium-chain saturated fatty acid triglyceride and 0.2g of (sorbitan xxx) were well mixed. Subsequently, a mixture of 15. 2mg was weighed into each aluminum container of 5ml for aerosol. Further, a mixture of freon 12 and 114, in the ratio of 1:1, of 84.8mg at a low temperature was filled into each container. Thereafter, an adaptor for metering 10.0ml per injection was attached to the container to produce inhalation medicine containing 5mg of the foregoing compound in one 21431~3 spray-type container of 5ml. For showing availability of the compounds of the present invention, the results of the pharmacological tests of the compounds will be given hereinbelow.
(roliplum xxx) in Table 3 is the compound represented by the foregoing structure as described in the foregoing Japanese First Patent Publication No. 50-157360. In, for example, Adv. Second Messenger Phosphoprotein Res., 22, 1 (1988), it is described to show specific inhibition to PDE IV.
Test 1 Action to Phosphodiesterase (PDE) IV Enzyme Activities Enzyme was partialy purified from human histiocytic lymphoma(U937) cytoplasm fraction by means of the Q-sepharose column according to the method of Nicholson and collaborators [Br. J.
Pharmacol., 97, 889 (1989)], and was reacted in a solution of 0.1mg/ml BSA (bovine serum albumin), 1mM EDTA (ethylenediaminetetra acetic acid), 5mM MgCl2 and 50mM Tris-buffer (pH 8.0) for 15 minutes at 30C
using 0.4 ~ M 3H-cAMP as substrate accodring to the method of Hidaka and collaborators [Biochem. Med., 10, 301 (1974)]. 3H-5'-AMP generated was separated by means of the cation exchange column, and the enzyme activity was determined by measuring a radioactivity amont.
A test compound was added. After incubations for 15 minutes at 30C, the substrate was added. Inhibition ratios were derived for respective concentrations assuming that the reaction without the test compound was 100%. By using the probit analysis, the concentration (IC50) showing the inhibition rate of 50% was derived. The results are shown in Table 3.
Table 3 compound No. PDE IV inhibitory activity IC50 (M) 1. Oxl o 8 3 6. 0 x 1 0~9 4 1. 1 x 1 o~8 6 6. 0 x 1 0~9 7 2. 0 x 1 o 8 8 1. 9 x 1 o~8 1 3 3. 3 x 1 0 9 1 7 2. 3 x 1 o 8 1 9 3. 8 x 1 0~9 2 3 1. 4 x 1 o 8 2 4 2. 3 x 1 0~9 2 6 8. 8 x 1 0~9 3 2 2. 5 x 1 o 8 3 6 1. 1 x 1 o 8 3 7 1. 9 x 1 o 8 3 8 2. 3 x 1 o~8 4 0 1. 0 x 1 o 8 4 2 8. 0 x 1 0~9 4 8 1. 1 x 1 0~9 roliplam 3. o x 1 0~7
Claims (8)
1. A 3-phenylpyrrolidine derivative of the following formula (I):
(I) wherein R1 is C1 - C4 alkyl;
R2 is tetrahydrofuranyl, C1 - C7 alkyl, C1 - C7 haloalkyl, C2 -C7 alkenyl, bicyclo [2.2.1] hept-2-yl or C3 - C8 cycloalkyl;
A is wherein R4 is C1 - C4 alkyl;
Y is -O-, -S-, -O-N=CH-, -NR5-wherein R5 is hydrogen, C1 - C4 alkyl, C2 - C4 alkylcarbonyl or pyridylmethyl, or single bond;
R3 is C1 - C7 alkyl which is unsubstituted or substituted by one or more substituents, or -(CH2)n-B
wherein n is an integer of 0 to 4, B is phenyl which is unsubstituted orsubstituted by one or more substituents, naphtyl which is unsubstituted or substituted by one or more substients, or heterocyclic residue which is unsubstituted or substituted by one or more substituents;
with the proviso that when -A-Y-R3 is R1 and R2 is not methyl at one time;
optical isomers, salts, N-oxide derivatives, hydrates or solvates thereof.
(I) wherein R1 is C1 - C4 alkyl;
R2 is tetrahydrofuranyl, C1 - C7 alkyl, C1 - C7 haloalkyl, C2 -C7 alkenyl, bicyclo [2.2.1] hept-2-yl or C3 - C8 cycloalkyl;
A is wherein R4 is C1 - C4 alkyl;
Y is -O-, -S-, -O-N=CH-, -NR5-wherein R5 is hydrogen, C1 - C4 alkyl, C2 - C4 alkylcarbonyl or pyridylmethyl, or single bond;
R3 is C1 - C7 alkyl which is unsubstituted or substituted by one or more substituents, or -(CH2)n-B
wherein n is an integer of 0 to 4, B is phenyl which is unsubstituted orsubstituted by one or more substituents, naphtyl which is unsubstituted or substituted by one or more substients, or heterocyclic residue which is unsubstituted or substituted by one or more substituents;
with the proviso that when -A-Y-R3 is R1 and R2 is not methyl at one time;
optical isomers, salts, N-oxide derivatives, hydrates or solvates thereof.
2. A compound as claimed in claim 1 wherein R1 is methyl, R2 is cyclopentyl.
3. A compound as claimed in claim 1 wherein R3 is -(CH2)n-B wherein n is integer of 0 to 2, B is heterocyclic residue which is unsubstituted or substituted by one or more substituents.
4. A compound as claimed in claim 1 wherein R3 is -(CH2)n-B wherein n is 1 or 2, B is heterocyclic residue having a ring of 6 atoms including 1 or 2 nitrogen atoms.
5. A compound as claimed in claim 1 wherein A is , Y is -O-, -S-, -NR5- wherein R5 is hydrogen, C1 - C4 alkyl, C2 - C4 alkylcarbonyl or pyridylmethyl, or single bond.
6. A compound as claimed in claim 1 wherein A is , Y is -O- or -NR5- wherein R5 is hydrogen, C1 - C4 alkyl, C2 - C4 alkylcarbonyl or pyridylmethyl.
7. A pharmaceutical composition comprising a compound as claimed in claim 1 as an active ingredient together with a pharmaceutically acceptable carrier therefor.
8. A antiasthmatic comprising a compound as claimed in claim 1 as an active ingredient together with a pharmaceutically acceptable carrier therefor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP37187/1994 | 1994-03-08 | ||
| JP3718794 | 1994-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2143143A1 true CA2143143A1 (en) | 1995-09-09 |
Family
ID=12490586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002143143A Abandoned CA2143143A1 (en) | 1994-03-08 | 1995-02-22 | 3-phenylpyrrolidine derivatives |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5545647A (en) |
| EP (1) | EP0671389A1 (en) |
| KR (1) | KR950032180A (en) |
| CN (1) | CN1121917A (en) |
| CA (1) | CA2143143A1 (en) |
| FI (1) | FI951052A (en) |
| HU (1) | HUT71891A (en) |
| NO (1) | NO950879L (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
| US5591776A (en) | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
| ATE214700T1 (en) * | 1995-06-06 | 2002-04-15 | Pfizer | TRIZYCLIC 5,6-DIHYDRO-9H-PYRAZOLO(3,4-C)-1,2,4-TRIAZOLO(4 3-ALPHA)PYRIDINES |
| US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| US6075016A (en) | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
| US5874437A (en) * | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| USRE37234E1 (en) * | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
| US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| JP2001504457A (en) * | 1996-11-01 | 2001-04-03 | ニトロメド インコーポレーテッド | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and methods of use |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US6069151A (en) * | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
| US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
| US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
| ES2242594T3 (en) * | 1999-01-15 | 2005-11-16 | Altana Pharma Ag | N-OXIDES OF PHENANTRIDINS WITH AN INHYDING ACITVITY OF PDE-IV. |
| DK1147103T3 (en) * | 1999-01-15 | 2005-08-29 | Altana Pharma Ag | Phenanthridine N-oxides with PDE-IV inhibitory activity |
| US6455554B1 (en) | 1999-06-07 | 2002-09-24 | Targacept, Inc. | Oxopyridinyl pharmaceutical compositions and methods for use |
| PL200923B1 (en) | 1999-08-21 | 2009-02-27 | Nycomed Gmbh | SYNERGISTIC COMBINATION OF PDE INHIBITORS AND ß₂ ADRENOCEPTOR AGONIST |
| US6376489B1 (en) * | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6680336B2 (en) | 1999-12-15 | 2004-01-20 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6313156B1 (en) * | 1999-12-23 | 2001-11-06 | Icos Corporation | Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors |
| US6348602B1 (en) | 1999-12-23 | 2002-02-19 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| MXPA03005581A (en) * | 2000-12-19 | 2003-10-06 | Hoffmann La Roche | Substituted pyrrolidines as ccr-3 receptor antagonists. |
| MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| CA2483752C (en) * | 2002-04-29 | 2011-03-29 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EA200501548A1 (en) | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | PHOSPHODYSTERASE INHIBITORS FOR INFERTILITY |
| MX2007001713A (en) | 2004-08-11 | 2007-07-13 | Donald L Barbeau | Noncardiotoxic pharmaceutical compounds. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (en) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS. |
| AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
| SG182567A1 (en) * | 2010-01-20 | 2012-08-30 | Sanofi Sa | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application |
| FR2955580A1 (en) * | 2010-01-28 | 2011-07-29 | Sanofi Aventis | New heterocyclic alkyl carbamate derivatives are fatty acid amide hydrolase inhibitors useful for treating or preventing e.g. nausea, eating disorders, renal ischemia, cancer, osteoporosis, senile dementia, lung diseases and dyskinesia |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
| EP3718557A3 (en) | 2013-02-25 | 2020-10-21 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| CA2920856A1 (en) | 2013-08-09 | 2015-02-12 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| WO2016033105A1 (en) | 2014-08-29 | 2016-03-03 | The Board Of Regents Of The University Of Texas System | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases |
| CN105001240A (en) * | 2015-05-28 | 2015-10-28 | 浙江长典医药有限公司 | Cefamandole nafate compound entity used for children and preparation thereof |
| US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3644398A (en) * | 1969-04-11 | 1972-02-22 | Robins Co Inc A H | 1-carbamoyl-3-phenylpyrrolidines |
| DE2413935A1 (en) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4- (POLYALCOXY-PHENYL) -2-PYRROLIDONE |
| GB9007762D0 (en) * | 1990-04-05 | 1990-06-06 | Beecham Group Plc | Novel compounds |
| GB9009395D0 (en) * | 1990-04-26 | 1990-06-20 | Orion Yhtymae Oy | Cyclic hydroxamic acids and their use |
| US5191084A (en) * | 1991-05-01 | 1993-03-02 | American Home Products Corporation | Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents |
| PT100441A (en) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE |
-
1995
- 1995-02-22 CA CA002143143A patent/CA2143143A1/en not_active Abandoned
- 1995-03-06 EP EP95103196A patent/EP0671389A1/en not_active Withdrawn
- 1995-03-06 US US08/399,341 patent/US5545647A/en not_active Expired - Fee Related
- 1995-03-07 HU HU9500680A patent/HUT71891A/en unknown
- 1995-03-07 NO NO950879A patent/NO950879L/en unknown
- 1995-03-07 FI FI951052A patent/FI951052A/en not_active Application Discontinuation
- 1995-03-08 KR KR1019950004706A patent/KR950032180A/en not_active Application Discontinuation
- 1995-03-08 CN CN95100997A patent/CN1121917A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR950032180A (en) | 1995-12-20 |
| NO950879D0 (en) | 1995-03-07 |
| NO950879L (en) | 1995-09-11 |
| HU9500680D0 (en) | 1995-04-28 |
| US5545647A (en) | 1996-08-13 |
| FI951052A (en) | 1995-09-09 |
| EP0671389A1 (en) | 1995-09-13 |
| FI951052A0 (en) | 1995-03-07 |
| CN1121917A (en) | 1996-05-08 |
| HUT71891A (en) | 1996-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2143143A1 (en) | 3-phenylpyrrolidine derivatives | |
| JP7264810B2 (en) | Cyclobutane- and Azetidine-Containing Monocyclic and Spirocyclic Compounds as Alpha V Integrin Inhibitors | |
| CN109153636B (en) | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | |
| ES2791315T3 (en) | Triazole agonists of the APJ receptor | |
| JP2020530446A (en) | Compounds, compositions, and methods | |
| HUE028684T2 (en) | Substituted isoquinoline derivative | |
| BRPI0718028A2 (en) | AZA-ADAMANTAN DERIVATIVES AND METHODS OF USE | |
| JP2022520236A (en) | Compounds, compositions, and methods | |
| BRPI0819719B1 (en) | DIPEPTIDIL PEPTIDASE-IV INHIBITION COMPOUNDS, METHODS OF PREPARATION OF THE SAME, AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AS AN ACTIVE AGENT | |
| WO2016046755A1 (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| EP2976338B1 (en) | N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors | |
| CN111484491B (en) | Substituted pyrido-cyclic compounds, process for their preparation and their use | |
| EP2968358A1 (en) | Novel choline kinase inhibitors | |
| WO2023280280A1 (en) | Fused-ring compound that acts as kras g12d inhibitor | |
| US10385036B2 (en) | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | |
| JP2023522863A (en) | Tricyclic compounds as EGFR inhibitors | |
| HRP20000585A2 (en) | Substituted bisindolymaleimides for the inhibition of cell proliferation | |
| EP3927699A1 (en) | Modulators of myc family proto-oncogene protein | |
| JPH07300455A (en) | 3-phenylpyrrolidine derivative | |
| BR112018008204B1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH IRREGULARITIES OF GLUTAMATERGIC SIGNAL TRANSMISSION AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
| CA3226724A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
| JP2021501778A (en) | Pyridopyrimidine compounds as mTORC1 / 2 double inhibitors | |
| JP2024506612A (en) | Tricyclic derivatives useful as PARP7 inhibitors | |
| EP4271377A1 (en) | Compounds and methods for modulating fxr | |
| WO2024026479A2 (en) | Cdk2 inhibitors and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |